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Under the Direction of Dr. Gabor Patonay 
ABSTRACT 
 
The United States Environmental Agency permits the use of 39 organophosphate pesticides. 
Many of these pesticides are acutely toxic and have lasting effect on human health. 
Organophosphates quickly metabolize in the body, therefore currently human exposure is studied 
by measuring the metabolic products in urine.  
In this work a suite of analytical methods was developed to determine the presence of un-
metabolized organophosphate pesticides in human serum. First mass spectroscopic detection 
methods were evaluated. Gas chromatograph coupled tandem mass spectrometer was used to 
compare the detection limits using chemical and electron impact ionization.  Positive chemical 
ionization was selected, because it provided better detection limits for this set of analytes.  
Liquid chromatograph coupled tandem mass spectrometry was also evaluated and was found 
advantageous over the gas chromatographic method for approximately 50% of the compounds. 
Positive atmospheric pressure chemical ionization was chosen for this group of compounds. 
Once the analytes were separated by detection methods, analytical separation methods were 
 compared: column and eluent was selected for liquid chromatography, column alone was 
selected for gas chromatography. 
Last step of the method development was to produce a suitable sample cleanup process.  
Solid phase extraction was not suitable because the very wide range of solubility characteristics 
and hydrolytic stability of the analytes. Lyophilization, liquid-liquid extraction methods were 
tested and compared. A multi step cleanup method was produced, which starts with liquid-liquid 
extraction using high pressure ethyl acetate in accelerated solvent extractor, solvent exchange 
and a lipid removal step. The concentrated extract then injected in a HPLC-MS-MS system then 
the same extract either directly injected in GC-MS-MS or further purified using headspace solid 
phase micro extraction before the GC-NS-MS step. 
The method was used with good results for analyzing samples collected from farm workers 
using OP pesticides. 
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  Betasil   Betasil   Betasil  
  C18  C18  Phenyl  
  Width: 2.1mm  4.6mm  4.6mm 4.6mm 
No. OP Length: 100mm   100mm   MeOH ACN 
1 Acephate 8.1  7.94  6.15 5.62  
2 Azinphos-methyl 21.83  19.35  20.53 17.11  
3 Bensulide 24.2  21.4  21.72 19.08  
4 Cadusafos* 25.64  22.39  21.05 17.59  
5 Chlorethoxyfos 26.88   -   N/F N/F E/B 
6 Chlorpyrifos 27.41  23.5  22.53 28.06 E/B 
7 Chlorpyrifos methyl 25.86  22.57  21.67 27.61 E/B 
8 Coumaphos 24.85  21.88  22.24 19.15  
9 Diazinon 24.8  21.83  21.18 17.92  
10 Dichlorvos (DDVP) 19.08   16.72   15.67 N/F E/B 
11 Dicrotophos 14.25  12.13  13.68 9.94  
12 Dimethoate 15.71  14.29  14.16 11.68  
13 Disulfoton 28.94  22.43  21.66 N/F  
14 Ethion 26.97  23.19  23.1 20.58  
15 Ethoprop 23.72   21.08   19.86 16.28   
16 Ethyl parathion 24.46  21.62  21.09 N/F E/B 
17 Fenamiphos 24.19  21.42  20.77 16.5  
18 Fenitrothion 23.36  20.76  20.64 N/F E/B 
19 Fenthion 24.83  21.9  21.82 N/F E/B 
20 Fonofos** 24.91   21.98   21.25 18.85   
21 Malathion 22.97  20.41  20.57 17.89  
22 Methamidophos 4.08  6.43  3.67 3.47  
23 Methidathion 21.66  19.18  19.75 16.86  
24 Methyl parathion 22.46  19.98  19.66 N/F E/B 
25 Mevinphos* 16.97   15.14   15.18 11.72   
26 Naled 21.52  18.96  18.47 N/F  
27 Oxydemeton methyl 12.79  10.67  12.34 10.22 split 
28 Phorate 25.4  22.27  21.29 N/F E/B 
29 Phosalone* 25.26  22.17  22.12 N/F E/B 
30 Phosmet 29.03   N/F   N/F N/F E/B 
31 Phostebupirim 26.79  23.13  22.04 19.27  
32 Pirimiphos methyl 24.72  21.71  20.69 17.56  
33 Profenofos 26.4  22.86  22 N/F E/B 
34 Propetamphos 23.21  20.64  19.87 17.68  
35 Sulfotepp 24.56   21.67   21.31 19.11   
36 Temephos 26.73  22.98  24.04 N/F E/B 
37 Terbufos 26.75  23.09  22.15 N/F  
38 Tetrachlorvinphos 24.28  21.51  21.03 17.53  
39 Tribufos (DEF) 28.58  24.31  23.17 20.08  
40 Trichlorfon 19.09   16.73   15.64 N/F E/B 
  
Table 15   Retenetion times of OP pesticides on Betasil C18 and Phenyl Columns (N/F: not 
found, E/B: extreme peak broadening) ......................................................................................... 94 
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   Aquasil C18 Chromolith RP 18e Zorbax SBC3 
  Width:   4.6mm  4.6mm   4.6mm  
No. OP Length:    100 mm   100 mm   100 mm  
1 Acephate  8.35  7.33  7.53 
poor 
peakshape 
2 Azinphos-methyl  20.12  18.42  19.43  
3 Bensulide  21.56  21.19  21.19  
4 Cadusafos*  22.76  22.51  22.19  
5 Chlorethoxyfos   20.1 Poor peak     N/F    N/F   
6 Chlorpyrifos  23.63  23.79  22.65  
7 Chlorpyrifos methyl  22.77 Poor peak 22.61  21.63  
8 Coumaphos  22.57  21.8  22.29  
9 Diazinon  22.32  21.67  21.75  
10 Dichlorvos (DDVP)   16.77   15.79   16.24   
11 Dicrotophos  13.8  11.73  14.13  
12 Dimethoate  14.12  12.42  14  
13 Disulfoton  22.47 Bad tailing 22.39 Smearing 21.4  
14 Ethion  23.55  23.59  22.58  
15 Ethoprop   21.45   20.39   20.63   
16 Ethyl parathion  21.86  21.25  20.97  
17 Fenamiphos  21.79  21.05  20.93  
18 Fenitrothion  21.04  19.91  20.15  
19 Fenthion  22.23  21.66  21.01  
20 Fonofos**   22.1   21.65   20.92   
21 Malathion  20.45  19.52  20.01  




23 Methidathion  19.26  18.08  18.86  
24 Methyl parathion  20.06  18.88  19.21  
25 Mevinphos*   15.26   13.96   15.91   
26 Naled  *  18.06   N/F  
27 Oxydemeton methyl  12.79  10.39  12.38  
28 Phorate  22.35  22.14  21.13  
29 Phosalone*  22.41  22.17  21.64  
30 Phosmet    N/F    N/F    N/F   
31 Phostebupirim  23.26  23.38  22.48  
32 Pirimiphos methyl  21.87  20.85  20.77  
33 Profenofos  23.31  23.14  22.29  
34 Propetamphos  20.64  19.79  20.07  
35 Sulfotepp   21.71   21.43   20.86   
36 Temephos  23.47  23.55  22.78  
37 Terbufos  23.17  23.33  22.23  
38 Tetrachlorvinphos  21.88  21.15  20.9  
39 Tribufos (DEF)  24.31  24.51  23.6  
40 Trichlorfon   15.27   14.17   15.88   
  
Table 16   Retenetion times of OP pesticides on Aquasil C18 and Chromolit RP 18e, Zorbax 
19 
SBC3 ............................................................................................................................................. 95 
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 Discovery HS F5 3µm Hypercarb Varian C18 
 Width:  4.6mm   4.6mm  4.6mm  
No. OP Length:  100 mm   100 mm   250mm    
1 Acephate 7.61  3.22  12.74  
2 Azinphos-methyl 20.61  N/F E/B 23.99  
3 Bensulide 22.21  22.62 tailing 24.65  
4 Cadusafos* 21.7  18.73  26.17  
5 Chlorethoxyfos N/F   N/F E/B N/F   
6 Chlorpyrifos 22.85  N/F E/B 27.53  
7 Chlorpyrifos methyl 22.12  N/F E/B N/F E/B 
8 Coumaphos 23.83  N/F E/B 25.62  
9 Diazinon 22.4  21.05  25.77  
10 Dichlorvos (DDVP) 16.8   N/F E/B 21.64   
11 Dicrotophos 13.39  9.33  16.69  
12 Dimethoate 14.86  10.46  18.43  
13 Disulfoton N/F  N/F  26.21  
14 Ethion 23.31  25.26 tailing 26.8  
15 Ethoprop 19.98   15.63   24.98   
16 Ethyl parathion 22.75  N/F E/B 25.28  
17 Fenamiphos 20.97  N/F E/B 24.88  
18 Fenitrothion 22.1  N/F E/B 24.7  
19 Fenthion 21.99  N/F E/B 25.77  
20 Fonofos** 22.02   8.23   25.92   
21 Malathion 21.27  18.7  24.23  
22 Methamidophos 4.28  1.43  12  
23 Methidathion 20.4  22.03  23.74  
24 Methyl parathion 21.57  N/F E/B 24.13  
25 Mevinphos* 15.59   N/F E/B 19.41   
26 Naled 18.55  N/F  N/F  
27 Oxydemeton methyl 11.57  8.23  15.35  
28 Phorate 22.02 tailing N/F  26.9  
29 Phosalone* 22.57  N/F  25.66  
30 Phosmet N/F   N/F E/B N/F   
31 Phostebupirim 22.73  20.45  27  
32 Pirimiphos methyl 26.26  N/F E/B 25.89  
33 Profenofos 22.25  N/F E/B 26.72  
34 Propetamphos 20.6  17.76  24.26  
35 Sulfotepp 21.92   17.32   25.21   
36 Temephos 23.59  N/F E/B 26.44  
37 Terbufos 22.96  N/F  26.87  
38 Tetrachlorvinphos 21.19  N/F E/B 25.09  
39 Tribufos (DEF) 23.01  N/F  28.5  
40 Trichlorfon 16.82   N/F E/B 19.38   
  
Table 17   Retenetion times of OP pesticides on Discovery HS F5, Hyper carb and Varian C18 
columns ......................................................................................................................................... 96 
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LIST OF ACRONYMS 
 
AChE Acetyl Cholinesterase Enzyme 
APCI Atmospheric Pressure Chemical Ionization 
CI Chemical Ionization 
DEDTP O,O-Diethyl Dithiophosphate  
DEP Diethyl Phosphate 
DETP O,O-Diethyl Dithiophosphate 
DMDTP O,O-Dimethyl Dithiophosphate  
DMP Dimethyl Phosphate 
DMTP O,O-Dimethyl Thiophosphate  
EI Electron Impact Ionization 
EPA Environmental Protection Agency  
GC Gas Chromatography 
HPLC High Pressure Liquid Chromatography 
LC Liquid Chromatography 
LOD Limit of Detection 
OP Organophosphate Pesticide 
OPICN Organophosphorus Ester-Induced Chronic Neurotoxicity  
OPIDP Organophosphate Induced Delayed Polyneurophaty 
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CHAPTER 1: INTRODUCTION AND GOALS 
 
Organophosphates (OP) are a very effective and widely used class of pesticides.  
Presently there are 39 organophosphate type pesticides registered with the Environmental 
Protection Agency (EPA) [1] 
OP pesticides became popular after the persistent organochlorine pesticides were banned in 
the 1970s. Their wide availability relatively low price, short half life in the environment and low 
susceptibility to pest resistance made them an attractive alternative.  
The total insecticide use in the United States has been declining: it has dropped approximately 
45% from 1980 to 2001, according to the latest available statistics from the EPA. The same time 
the share of OP pesticides went up from 58 t 70% of the total use. 
 
R:    Methyl or Ethyl 
Y:    O or S 
X:    Specific Organic Group 
Figure 1   General Structure of  Organophosphate Pesticides 
 
Using the above general structure, the organophosphate pesticides of interest can be grouped 
































(herbicide, not in the 40 
compounds of interest) 
S-alkyl phosphorothioate 













































Table 1   Groups of Organophosphates   R, R1, R2, R3 : Ethyl, methyl.   X: Specific Group 
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Toxicity 
Inhibition of Acetyl Cholinesterase: Acute Cholinergic Syndrome 
The primary reason for OP toxicity is its inhibition of the acetyl cholinesterase (AChE) 
enzyme: 
Acetyl cholinesterase is found in many tissues but its role mostly is understood in the nervous 
system. It hydrolyzes the neurotransmitter acetylcholine, terminating its action. It is essentially 
the “off switch” of the neuroimpulse. If the AChE is inhibited it leaves the synapse in the “on” 
state hence the paralytic effect of the OP. 
During inhibition the OP mimics the acetyl cholinesterase phosphorylation of the active site. 
Hydrolysis of the phosphoryl-AChE is very slow so the enzyme’s catalytic potential is lost.  
Inhibition of the AChE enzyme becomes irreversible when the methoxy or ethoxy groups 
hydrolytically removed from the absorbed portion of the organophosphate pesticide. This process 
is called aging Phosphorylated AChE undergoes two reactions at a very slow rate: recovery and 
aging. Recovery is the hydrolytic removal of the phosphate moiety from the AChE enzyme. The 
half life of the OP-AChE adduct depends on R1 and R2. In case of pesticides it takes place in 
order of hours. 
The other important process is aging. Aging is the dealkylation of the OP moiety in the OP-
AChE complex. Once aging takes place, the inhibited AChE can not be reactivated. 
 
- Symptoms of acute OP poisoning are: 
- Nausea, vomiting, abdominal cramps, diarrhea; 
- Excessive salivation, rhinorrhea; 
- Headache, vertigo; 
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- Fixed pinpoint pupils, blurred vision ocular pain; 
- Muscle twitches, especially of face, tongue and neck; 
- Difficulty in breathing, primarily due to excessive secretion and bronchoconstriction 
- Random jerky movements, convulsions; 
- Respiratory paralysis, death. 
 
Depending on the dose, type/toxicity of the OP pesticide and quality of health facilities, the 
reported mortality rates are between 4 % and 29 %. 
Recovery of inhibited AChE in the nervous system is about 1 week in experimental animals 
and it is believed to be the same in people. In untreated patients it takes 5-7 weeks for the AChE 


























Figure 2   Esterase Inhibition by Organophosphate R: Ethyl or methyl,  X: Specific group 
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Intermediate Syndrome 
The intermediate syndrome is a set of symptoms that may develop in patients after recovery 
from acute OP pesticide poisoning. It too is caused by esterase inhibition and manifests itself 
through muscle weakness tremors and respiratory distress. Since it develops after the acute 
cholinergic syndrome but before the “OP induced delayed neuropathy, it was coined as the 
“Intermediate syndrome” 
Organophosphate Induced Delayed Polyneurophaty (OPIDP) 
OPIDP is a set of symptoms caused by OP poisoning but with an onset of 1-3 weeks after the 
initial acute poisoning. Its manifestations are: muscle weakness, cramps in the arms and legs. 
Recovery is slow and usually incomplete. 
The cause of OPIDP is the OP induced inhibition of the neuropathy target esterase (NTE) 
 
Organophosphorus Ester-Induced Chronic Neurotoxicity (OPICN) [2] 
OPICN is produced by acute or multiple subclinical doses of organophosphorus compounds. 
Clinical signs, ranging from weeks to years after exposure, consist of neurological and 
neurobehavioral abnormalities. These abnormalities continue for a prolonged time, and are 
caused by damage to the central and peripheral nervous system.  
Most examples in the literature are observed after acute OP poisoning. The OP exposure 
causes lesions on the brain which results  in neurological symptoms: increased incidence of 
depression, irritability, confusion, and social isolation. Also there is observable decreased verbal 
attention, visual memory, motoricity, and affectivity.  
There is more information on acute exposure induced OPICN, probably because the cause is 
well defined and the dose is quantifiable. 
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For our studies however, effects of repeated small doses – which do not cause acute poisoning 
– is more relevant.  
Professional pesticide applicators and farmers exposed to organophosphate pesticides show 
the following symptoms: anxiety, diminished vigilance and reduced concentration. Kaplan et 
al.[3] observed long-term cognitive problems in concentration, word finding, and short-term 
memory in individuals exposed to low subclinical levels of chlorpyrifos. Sheep dippers exposed 
to OP pesticides experienced significant neuropsychological problems.[4, 5] Male fruit farmers 
who were chronically exposed to OP insecticides showed significant increase of their reaction 
time.[6] The same symptoms were observed in female pesticide applicators, with the addition of  
reduced motor steadiness, and increased muscle tension, depression, and fatigue . Workers 
exposed to the OP insecticide quinalphos during manufacturing, exhibited changes in central 
nervous system function: memory loss, impaired vigilance, slow learning and motor deficits. The 
AChE activity of these workers was normal..[7]  
Many rescue workers and some people who did not develop any acute symptoms during the 
Tokyo nerve gas attack later developed chronic, persistent memory loss three years and nine 
months after the attack.[8, 9] Pilkington et al.[10] reported strong correlation between chronic 





The main routes of exposure are oral, dermal or inhalation. 
 
Oral Exposure 
The main route of the exposure of the general population to OP pesticides is ingestion via 
food or drinking water. Regulatory controls of pesticide use is designed to keep the resulting 
pesticide levels insufficient to cause adverse health effects. 
Ingestion of substantial amounts can occur either deliberately (suicide attempts) or 
accidentally as a result of mistaken identity or poor handling techniques. 
Dermal Exposure 
The main cause of dermal exposure is handling of OP pesticides, during manufacturing or 
application. Dermal penetration is varying, depending the carrier solvent: usage of solvents 
which can penetrate the skin – such as acetone – cause higher uptake than water based 
suspensions. Absorption of OP pesticidesis also dependent on the hydratation and temperature of 
skin.  
Inhalation 
Inhalation of OP pesticides is usually the result of use of sprays, mists and powders. 
Absorption is fast and almost complete. The pesticide enters in the circulatory system without 
passing through the liver. Exposure through inhalation is usually combined with exposure of 
eyes and mucous membranes. 
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Distribution 
In rhesus monkeys, 40% of intravenously administered radiolabelled diazinon, was excreted 
in 24 hrs. (urinary excretion) This was followed by a slow and almost constant 5% / day 
excretion for 3 – 7 days. Dermal exposure of humans followed a similar pattern. 
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OP Metabolism [11] 
Many tissues like skin, gut lung and kidneys contain enzymes that can metabolize Ops, the 
main sites are the liver and blood. Mammalian OP metabolism involves many enzymes and 
possible pathways. The dominant metabolic process will depend on the type of OP, the exposure 




Figure 3   Non Persistent Pesticide: Concentration Change in Blood and in Urine [12] 
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Table 2   Non-Specific Metabolites of OP Pesticides and their Structures 
Chemical Name Abbreviation Structure 


























































The A- esterases are a group of enzymes which are able to hydrolyze a broad range of 
substrates, including OP pesticides. They are present in a number of tissues: in the liver, the 
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intestine and in serum. Most studied example is the hydrolysis of paraoxon to diethyl phosphate. 
(Figure 4) Many similar OP hydrolyze to the respective dialkyl phosphate, following a similar 
pattern. 
The products of the hydrolysis are excreted in the urine. This hydrolytic process results in the 
removal of the “leaving group”, which subsequently can be analyzed and used as a biomarker for 
that specific OP. These removed leaving groups are also known as “specific metabolites”  









Figure 4   Paraoxon Hydrolysis to diethyl phosphate 
Carboxylesterases  
Carboxylesterases (CaEs) are present in mammalian plasma and in many tissues including 
liver, kidney, brain, intestines, muscles, etc. Their normal physiological role is the metabolism of 
lipids. They also contribute to the detoxification of OP pesticidesthrough two mechanisms: 
1. Hydrolysis of carboxyl ester side chains.(Figure 5) 












































Figure 7   Oxidative Desulphuration of Parathion 
 
Microsomal Oxigenases 
Microsomal oxigenases are a family of enzymes that contain cytochrome P450 and/or flavin. 
These enzymes are found in most tissues but their predominant location is the liver. Microsomal 
oxigenases catalyze several reactions: 
- Oxidative desulfuration of OP pesticidessuch as conversion of parathion to paraoxon 
(Figure 7). The resulting oxon is much more toxic. 
- Oxidative O and N-dealkylation and dearylation 
- Thioether oxidation 
- Side chain oxidation 
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Figure 8   Metabolism of Chlorpyrifos 
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Determining OP pesticide exposure  
Non – assay methods. 
Exposure to pesticides may be estimated by using empirical mathematical formulas based on 
usage, time of exposure, exposed skin area and other factors. [4, 5]. Of course these methods are 
only estimates, not actual measurements. 
Urinary Assay of OP Metabolites 
Most modern pesticides and all of the organophosphates of interest are “non persistent”, 
which means that they quickly metabolized, the intact pesticide is only present in the 
bloodstream – in any measurable amount - for a few hours to a few days 
Traditionally most of the studies are carried out using urine samples analyzing for OP 
metabolites. The two main reasons are that urine samples are much easier to obtain than blood 
and that the metabolite concentration – time function gives a wider window of delectability. 
Examples of urinary assays of organophosphate metabolites: 
Hardt Et. Al. [13]used liquid-liquid extraction followed by centrifugation and drying under 
vacuum. After derivatization overnight with 2,3,4,5,6 pentafluorobenzyl bromide. After a second 
liquid-liquid extraction the reconstituted sample was separated with gas-chromatography (GC). 
The detector was mass spectrometer. 
Bravo et al. [14] greatly simplified the above method by first lyophilizing the urine samples 
then using liquid extraction with a blend of acetonitrile and ethyl ether. Just like in the previous 
example, the OP metabolites being highly polar compounds, had to be derivativized to make 
them suitable for GC separation. In this case the derivatizing agent was 1-Chloro-3-iodopropane.  
Using metabolites in urine as biomarker has drawbacks however; metabolites are much less 
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specific. Most OP pesticidesmetabolize to one of the seven dialkyl phosphates: 
Second source of error is that the OP pesticidespath of breakdown is often similar to the 
metabolic pathway. As a result a person may ingest a breakdown product, which is also the target 
compound of the assay. Nonetheless today the preferred method of determining OP pesticide 
exposure is the urinary assay of metabolites.  
 
Detection of OP Pesticides in Blood/Serum/Plasma 
Being able to detect the unchanged pesticide solves the above mentioned, but because the 
concentrations in blood drop rapidly, (Figure 3) it requires a more sensitive detector. On the 
other hand the unmetabolized form of these compounds is more lipophilic than the metabolite, 
which should make sample cleanup and separation somewhat easier. 
Measuring the parent compounds in blood or blood products has other advantage; it is a 
regulated fluid. It means that blood volume is constant, unlike the urine volume in the human 
body. Therefore no dilution-correction needed when using serum, plasma or whole blood.[15] 
Two review articles [16, 17] summarize the most frequently used methods in OP analysis in 
whole blood, plasma or serum matrix. This review also uses independent searches of “ISI web of 
science”, focusing on assays OP compounds, blood / serum / plasma as matrix and –for the most 
part – mass spectrometer as a detector. The results are tabulated in Table 6 - Table 8, grouped by 
methods of separation 
The first group of methods, listed in Table 6 list recent works based on GC. 
The most recent work by Mushoff et. Al. [18] used solid phase microextraction, (SPME), GC 
and mass spectrometric detection with electron impact ionization and single ion monitoring to 
determine 22 OP pesticides. Detection limits were reported between 10 and 300 ng/mL. SPME is 
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a clean and simple technique the method is hampered though with low recoveries. 
The lowest limits of detection was achieved by Barr and her coworkers [19] They analyzed 29 
contemporary pesticides in blood, 9 of them OP-s. using GC coupled with high resolution mass 
spectrometer they achieved 0.5 to 2 ppt detection limits  This is probably the most important and 
applicable method four our purposes; the LOD-s are likely low enough to study background 
levels of exposure. 
17 
 
Goals and Objectives 
To develop an analytical method to measure the non metabolized form of all 39 EPA 
registered organophosphate pesticides in human serum as matrix. 
Test various cleanup methods such as solid phase extraction, liquid-liquid extraction, 
lyophilization, and their automated variants for feasibility. Determine recoveries for each 
analyte. While high recovery is important, focus of the cleanup has to be removal of 
interfering contaminants. 
Test HPLC and GC for analytical separation methods, optimize separation parameters. 
Determine Limits of Detection, Limits of Quantitation. 
Study the robustness of the method. (Sensitivity to parameter variations.) 
Study the stability of OP pesticides at different temperatures. 
Study the stability of organophosphorus pesticides id blood and means to stabilize it. 






Experimental Choices Considerations 
Cleanup First Choice:   
For all sample cleanup / pre-
concentration steps the main 
considerations are: 
1.         Recovery 
2.         Purity (not to extract compounds 
interfering with further steps of the 
analysis) 
3.         Feasibility for automation / 
Sample throughput  
  SPE 
  LLE 
   
   
 
   




GC Will work for the intact OP pesticides 
  HPLC Probably preferred for the metabolites 
or heat labile OP-s. Interfacing with 
HRMS may be a problem 
  
Detection HRMS - First Choice,  
  MS-MS - Second choice, but should give good 
results with the newer instruments. 
(Quantum, Sciex 4000) 
        
Stability Study This is like a project in a project: it may run parallel with the above outlined 
parts on a limited number of OP pesticides 












































































































































































































































































































































































Abbreviation Chemical Name 
BTA  1,2,3-benzotriazin-4(3H)-one 
CIT  5-chloro-1-isopropyl-(1H)-1,2,4-triazol-3-ol 
CMHC  3-chloro-7-hydroxy-4-methyl-2H-chromen-2-ol 
DEAMPY  2-(diethylamino)-6-methylpyrimidin-4-ol  
DEDTP  O,O-Diethyl Dithiophosphate  
DMDTP  O,O-Dimethyl Dithiophosphate  
IMPY  2-isopropyl-4-methyl-6-hydroxypyrimidine 
MSMB  Methysulfonyl methylbenzazimide 
















DEDTP metabolites  
Acephate  —  —  —  —  —  —  Acephate, 
       methamidophos 
Azinphos-methyl  X  X  X  —  —  —  BTA, MSMB 
Bensulide  —  —  —  —  —  —  — 
Cadusafos  —  —  —  —  —  —  — 
Chlorethoxyphos  —  —  —  X  X  —  — 
Chlorpyrifos  —  —  —  X  X  —  3,5,6-TCPY 
Chlorpyrifos-methyl  X  X  —  —  —  —  3,5,6-TCPY 
Coumaphos  —  —  —  X  X  —  CMHC 
Diazinon  —  —  —  X  X  —  IMPY 
Dichlorvos (DDVP)  X  —  —  —  —  —  — 
Dicrotophos  X  —  —  —  —  —  — 
Dimethoate  X  X  X  —  —  —  — 
Disulfoton  —  —  —  X  X  X  — 
Ethion  —  —  —  X  X  X  — 
Ethoprop  —  —  —  —  —  —  — 
Ethyl parathion  —  —  —  X  X  —  p-Nitrophenol 
Fenamiphos  —  —  —  —  —  —  — 
Fenitrothion  X  X  —  —  —  —  — 
Fenthion  X  X  —  —  —  —  — 
Malathion X X X — — — Malathion dicarboxylic acid,  
        mono-carboxylic acid 
Methamidophos  —  —  —  —  —  — Methamidophos  
Methidathion  X  X  X  —  —  —  — 
Methyl parathion  X  X  —  —  —  —  p-Nitrophenol  
Mevinphos  X  —  —  —  —  —  — 
Naled  X  —  —  —  —  —  — 
Oxydemeton-methyl  X  X  —  —  —  —  — 
Phorate  —  —  —  X  X  X  — 
Phosalone  —  —  —  X  X  X  — 
Phosmet  X  X  X  —  —  —  — 
Phostebupirim 
(tebupirimphos)  —  —  —  —  —  —  — 
Pirimiphos-methyl  X  X  —  —  —  —  DEAMPY  
Profenofos  —  —  —  —  —  —  — 
Propetamphos  —  —  —  —  —  —  — 
Sulfotepp  —  —  —  X  X  —  — 
Temephos   X  X  —  —  —  —  — 
Terbufos  X  X  X  X    
Tetrachlorvinphos  X  —  —  —  —  —  — 
Tribufos  —  —  —  X  X  —  — 
Trichlorfon  X  —  —  —  —  —  — 
Table 5   Specific and non specific metabolites of OP pesticides 
Abbreviations:   —: not applicable, X: exposure to the pesticide listed, DMP, DMTP,DMDTP, DEP, DETP, DEDTP 
see; BTA, CIT, CMHC, DEAMPY; DEDTP, DMDTP, IMPY MSMB: see Table 4 
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Analytical Separation MS Results 
No Author Publ. Amount Type Recovery 
[%] 
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Table 6   Assay of OP Pesticides In Serum, Plasma or Whole Blood - Gas Chromatography 
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Analytical Separation MS Results 

























































            
            
Table 7     Assay of OP Pesticides In Serum, Plasma or Whole Blood - Liquid Chromatography 
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Analytical Separation MS Results 
No Author Publ. Amount Type Recovery 
[%] 








































GC DB5 MS  
30m X .25mm 
X .1µm 
NPD  8 OP 
esters 
 










72-83 % GC DB5 MS  
30m X .32mm 
X .1µm 


























            
            
            
Table 8   Assay of OP esters In Serum, Plasma or Whole Blood  
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No. OP Native Labeled 
1 Acephate X X, D6 
2 Azinphos-methyl X ─ 
3 Bensulide X X, D14 
4 Cadusafos* X ─ 
5 Chlorethoxyfos X ─ 
6 Chlorpyrifos X X, D10 
7 Chlorpyrifos methyl X X, D6 
8 Coumaphos X X, D10 
9 Diazinon X ─ 
10 Dichlorvos (DDVP) X ─ 
11 Dicrotophos X ─ 
12 Dimethoate X X, D6 
13 Disulfoton X X, D10 
14 Ethion X ─ 
15 Ethoprop X ─ 
16 Ethyl parathion X X, D10 
17 Fenamiphos X ─ 
18 Fenitrothion X ─ 
19 Fenthion X X, D6 
20 Fonofos** X X, 13C6 
21 Malathion X X, D10 
22 Methamidophos X X, D6 
23 Methidathion X ─ 
24 Methyl parathion X ─ 
25 Mevinphos* X ─ 
26 Naled X ─ 
27 Oxydemeton methyl X X, D6 
28 Phorate X X, 13C4 
29 Phosalone* X ─ 
30 Phosmet X X, D6 
31 Phostebupirim X ─ 
32 Pirimiphos methyl X ─ 
33 Profenofos X ─ 
34 Propetamphos X ─ 
35 Sulfotepp X X, D20 
36 Temephos X ─ 
37 Terbufos X X, 13C4 
38 Tetrachlorvinphos X ─ 
39 Tribufos (DEF) X ─ 
40 Trichlorfon X ─ 
Table 9   Available Native OP pesticides and their Labeled Reference Compounds [32] 
Abbreviations: X: compound is available; ─: compound is not available, Dn: n number of Hydrogen Atoms 





General development strategy 
 
Our goal was as stated in the introduction, to develop a method to detect and measure 
trace concentration of the EPA approved OP pesticides. The difficulty of the project lies 
in the fact that these compounds encompass a very wide range of concentrations many of 
them are labile and all of them are subject of enzymatic degradation while in the matrix. 
Possible matrices – other than whole blood – are serum and plasma. 
We choose serum as matrix of preference, mainly because of easier cleanup and 
availability. 
The development process started with determining the correct mass spectrometric 
detection method. Detection has to be developed in conjunction with the separation 
techniques applied. Analytical separation techniques such as choice of solvents, effect 
decisions made at the detection part of the project, at the same time one needs a detection 
method to develop any analytical separation.  
 
• First, GC-MS was evaluated electron impact  ionization was compared with 
chemical ionization. 
Chemical ionization positive polarization was chosen. 
• Tandem mass spectrometry: MS-MS fragmentation was optimized and ions 
chosen 
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• LC/MS method was chosen (APCI positive mode) then MS-MS transitions were 
selected , parameters optimized. 
• HPLC method was finalized 
 
Sample Cleanup section 
Cleanup methods evaluated: 
• SPE was not considered because previous experience and the range of compounds 
involved with varying physical and chemical properties.  
• Freeze drying followed with solvent extraction was tried – not chosen 
• Liquid-liquid extraction on solid carrier (ChemElut) was tested with better results 
• Based on the promising results of the ChemElut method, accelerated solvent 
extraction (ASE)was tried and proved very successful. 
• ASE was optimized proved to be successful 
• A “normal phase chromatography” like additional cleanup step was developed 
using the “Rapid Trace” automated SPE instrument. It is to further purify the 
serum extract and make it usable. In a GC application 
• As an alternative to the second step cleanup headspace solid phase 
microextraction  
• Checked for accuracy and precision 




CHAPTER 2: GAS CHROMATOGRAPHY AND TANDEM MASS 
SPECTROMETRY 
 First step in the development process was to establish a method of detection: without 
detection one can not study separations. In our laboratory the most sensitive detectors are 
the mass spectrometers. The available instruments were GC coupled TSQ-7000 triple 
quadropole mass spectrometers and the newer LC coupled TSQ-Quantum Ultras, also of 
the triple quadropole type. We also have a MAT-95 high resolution sector instrument, but 
decided against using it mainly because of the limited availability and reliability issues at 
the time.  
The initial task was to determine the preferred ionization form for both: liquid 
chromatography (LC) and gas chromatography (GC) coupled systems. The selection 
process started with the GC-MS-MS system. After initial experiments it became apparent 
that chemical ionization – being a soft ionization mode – yield a higher proportion of 
molecular ions than electron impact ionization. For that reason chemical ionization (CI) 
was chosen. Later in this chapter actual limits of detections will be compared and the 
choice of CI quantitatively justified.  
Process to optimize mass spectrometric parameters for GC-MS-MS systems. 
When deciding on a detection method for a group of compounds, first the followings 
have to be decided: 
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1. Type of ionization:  The main modes are electron impact ionization(EI) and 
chemical ionization.(CI) The polarity of ionization is always positive in EI, in 
CI however it can be either positive or negative. 
2. Ion selection:  Two transitions have to be selected: one for quantitation, one for 
confirmation. 
3. Once the transitions are selected, the collision energy needs to be optimized. 
Some of the parameters were not optimized but used at or close to their default value.  
 CI EI 
Filament Current 300 mA 1300 mA 
Source temperature 150°C 180°C 
Reagent Gas Methane @ 1500 mT  
Table 10   Non optimized MS parameters 
 
Increasing filament current may increase signal strength but greatly decreases service 
life. Elevating source temperature will increase reaction rate, but also cause 
decomposition of thermally labile molecules. Lower source temperatures also cause 
increased fouling of the CI source and accelerate signal loss. 
Determining Ionization type and ion selection 
First individual solutions of the analytes were prepared at 2 µg/mL concentration in 
toluene. Based on prior literature, [18, 21-24] and availability at the time, W&J-s DB-5 
MS column was selected for initial testing. The column is 30m in length, has 0.25mm 
internal diameter and 25µm coating thickness. 1 µL of the pure analyte solution was 
injected and the developing chromatogram observed. Once the analyte peak was detected, 
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retention time recorded and one of more dominant ion selected. Preferably one of the ions 
of interest a molecular ion, but OP pesticides being often labile, it is not always possible.  
After one or more potential parent ion was selected, a second injection was made. This 
time the MS was set to product ion scan: quadropole one selects the parent ion, 
quadropole two fragments the parent ion and quadropole three was scanning the 
fragmentation products. Observing the product ions of each parent ion, two or three 
promising transition was selected. For each of these transitions (parent ion -> product 
ion)  a selected reaction monitoring (SRM) table was set up with different collision 
energies. Collision energy is the voltage difference between the last lens before 
quadropole 2 (Lens 2-3) and the first lens after quadropole two (Lens 3-1). This is the 
potential difference, that accelerate the parent ion (select in quadropole one) down on 
quadropole two. Quadropole two is filled wit low pressure ( ~2 mTorr) argon. The parent 
ions hitting the argon atoms break up, producing the product ions. At a set argon 
(collision gas) pressure, the pattern of fragmentation and the amount of product ions 
depend on the collision energy. For each transition of interest, the collision energy had to 
be optimized. The before mentioned SRM table is the instrument of collision energy 
optimization. A third injection was made in SRM mode, covering all transitions and 
collision energies of interest. After the GC-MS-MS run, for each transition and collision 
energy setting the chromatographic curve was plotted and the respective peaks integrated. 
For each transition the area count – collision energy curve was plotted and the optimum 
collision energy determined. This process is shown in Figure 9-Figure 12. 
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This process was repeated for each analyte in positive chemical ionization. For 
electron impact and negative chemical ionization, only the full scan (parent ion selection) 




















Figure 9   Simple temperature gradient to determine GC properties of  OP compounds 
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F:\OldGCWork\041229_07 12/29/2004 12:14:38 PM Chlorpyrifos Me
OP 1:10 dil stock Sol in ACN in ACN Q1 fs POS   CI
RT: 0.00 - 13.02
























3.15 10.043.63 10.809.373.91 7.864.75 11.20 12.27 12.6511.927.666.115.47 6.87 8.38
NL:
8.90E8
TIC  MS 
041229_07
041229_07 #686 RT: 8.97 AV: 1 NL: 1.82E8
T: + c CI Q1MS [50.00-500.00]


















































F:\NewGC\060630\060816_msmsFS08 8/21/2006 5:19:53 PM Chlorpyrifps Methyl
Chlorpyrifps Methyl, 2ppm in toluene msmsFS
RT: 0.00 - 13.01
























8.678.13 9.999.316.58 12.797.817.27 10.35 11.106.125.29 11.63 12.325.415.12
NL:
2.91E6
TIC  MS 
060816_ms
msFS08
060816_msmsFS08 #1106-1108 RT: 9.38-9.39 AV: 3 SB: 43 9.28-9.35 , 9.43-9.52 NL: 8.03E5
T: + c CI ms2 324.00@cid15.00 [50.00-400.00]









































RT: 0.00 - 13.01












































TIC F: + c CI SRM ms2 
322.00@cid10.00 
[289.70-290.30]  MS  ICIS 
060816_msmsFS09
NL: 1.44E6
TIC F: + c CI SRM ms2 
322.00@cid13.00 
[289.70-290.30]  MS  ICIS 
060816_msmsFS09
NL: 1.29E6
TIC F: + c CI SRM ms2 
322.00@cid16.00 
[289.70-290.30]  MS  ICIS 
060816_msmsFS09
NL: 8.70E5
TIC F: + c CI SRM ms2 
322.00@cid19.00 
[289.70-290.30]  MS  ICIS 
060816_msmsFS09
NL: 4.19E5
TIC F: + c CI SRM ms2 
322.00@cid22.00 
[289.70-290.30]  MS  ICIS 
060816_msmsFS09
NL: 1.73E5
TIC F: + c CI SRM ms2 
322.00@cid25.00 
[289.70-290.30]  MS  ICIS 
060816_msmsFS09
NL: 5.20E4
TIC F: + c CI SRM ms2 
322.00@cid28.00 
[289.70-290.30]  MS  ICIS 
060816_msmsFS09
NL: 1.29E4
TIC F: + c CI SRM ms2 
322.00@cid31.00 
[289.70-290.30]  MS  ICIS 
060816_msmsFS09
Figure 11   Area counts for clorpyrofos methyl 322 -> 290 transition at different collision 
energies 
























































Figure 13   Retention times for OP compounds on 30m .25mm X 25µm DB-5 MS column, linear 
temperature gradient. 
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Chapter 2  Dicussion 
When developing the GC-MS-MS part, there were two questions to consider. 
The first one is the selection of ionization mode. Using MS and MS-MS, the available 
ionization modes are EI, CI positive and negative polarity. Most of the available literature 
uses EI. [8]-[14]. The reason for this is probably twofold: EI is more economical in the 
sense that it produces multiple fragments in the ion source. As a result a compound can 
be identified from the main ions or fragments and their ratios. One does not need tandem 
mass spectrometer to produce fragments. The second reason is probably more practical: 
EI ions form in a partially open ion source. It remains clean longer than CI sources. CI 
sources or “ion volumes” are closed to the outside, save the few holes needed for material 
transport. Inside is the end of the GC column, and the reagent gas – most often methane – 
bombarded by the electron beam. As a result, contaminants from the sample leaving the 
GC column and their decomposition products tend to coat the inside of the ion volume. 
Once the inside of  the source becomes less conductive it also less effective, resulting in 
loss of sensitivity. 
Chemical ionization on the other hand has the advantage of the more controlled ion 
formation. To maximize sensitivity, our focus was to generate as much as possible 
molecular ion or a close fragment where unavoidable. Tandem mass spectrometers were 
available, these ions could be fragmented at a later stage.  
Using CI the choice is between positive and negative ionization. All things being equal, 
analyzing biological samples, negative ionization sometimes has an advantage. It is easier 
to ionize a compound in positive mode because it is easier to add a charge – usually a 
proton – to a molecule. In negative ionization, the removable proton (removable proton) 
39 
has to be there the first place. So if the molecule of interest ionizes in negative mode, the 
background is likely to be lower.  
OP pesticides however pose a particular problem: they tend to break apart in negative 
ionization. When this happens, often the non-specific part (phosphate-methyl, ethyl ester, 
thio-ester) is dominant.  
These issues can be demonstrated on the example of malathion, a very common 
pesticide. Figure 15 shows the many fragments produced by EI. CI, positive ionization 
(Figure 16 ) produces mainly the molecular ion (331), an adduct (C2H5+) and one more 
ion which created with a loss of an ethoxy. Negative chemical ionization chiefly produces 
the ion with the m/z of 157.  As it shown on Figure 17, it is a very non specific fragment. 
In a crowded separation it may come from many different compounds, such as Fonofos 
and Dimethoate. For this reason, CI positive was chosen as preferred ionization mode. 
For gas chromatography portion of the analytical separations part, most authors used 
either DB-5 / DB-5MS (5% phenyl, methyl polysiloxane) type columns or HP1701 





















































































































































Figure 17   Major fragments of malathion in CI negative mode 
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When looking for correlations in the GC section, the first approach is to plot retention 
time as a function of published[33] vapor pressure data. Since vapor pressure covers a 
wide range of values, logarithmic scale is useful. Figure 18 shows these vapor pressure 
values. It is tempting to find two groups, represented by lines A and B, but examining 
line B and the compounds it corresponds to, there is no structural commonality. (Table 11 
) 







































































S CH2 CH2 CH2S
O
5    Oxydemeton methyl 
 
Table 11  Compounds of line B (GC) 
Next step is to look at the outliers at an area where the vapor pressure is the same but 
the retention time is markedly different. Such is the boxed area on Figure 18. The two 
most extreme outliers are acephate and methamidophos. Both are very water soluble, so it 
is useful to factor in hydrophilic – hydrophobic properties in the investigation. Kow 
values, describe a compound hydrophobicity.  
Next, a retention factor “R” was proposed to predict an OP retention time (DB-5 
column, linear temperature gradient) along with the equation R = log(Kow) - a ∗ log(P). 
The correlation factor for Retention time –R factor arrays was calculated for several “a” 






















Figure 19   Correlation factor analysis  
Calculating the R value for an OP using the R = log(Kow) - a ∗ log(P )equation, the 
retention time of an OP may be easily predicted.  
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R = log(Kow) - 1.5 x log(P) 
 
Figure 20  Predicting OP retention times in GC 
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R = log(Kow) - 1.5 x log(P) 
 
Figure 21  Predicting OP retention times in GC – outliers (Oxydemethon  methyl, dicrotophos,  






  predicted actual 
Cadusafos 7.8 8.0 
Chlorethoxyfos 8.2 7.6 
Chlorpyrofos Me 9.8 9.4 
Diazinon 8.3 8.5 
Disulfoton 8.9 8.6 
Et Parathion 9.7 9.4 
Fenamiphos 10.2 10.1 
Fenitrothion 8.2 9.2 
Fenthion 10.4 9.4 
Fonofos 8.4 8.5 
Malathion 8.3 9.3 
Me Parathion 9.8 9.0 
Mevinphos 6.3 6.6 
Naled 5.9 5.5 
Phorate 7.9 8.0 
Phosalone 10.9 11.7 
Profenofos 10.8 10.2 
Sulfotepp 8.7 7.9 
Terbufos 7.6 8.4 
Table 12   GC predicted and actual retention times 
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CHAPTER 2   APPENDIX 
 
Appendix A CI Positive, negative and EI full scans 
These MS full scan experiments were necessary for the development of the GC-MS-
MS par t of the method. Unlike the LC –MS portion, few automated tools are available. 
Acetonitrile based stock solution was diluted with toluene to produce 1 µg/mL samples.2 
µL of these were injected on DB-5 MS column, using a linear temperature gradient. 

















CI positive 150 1500 300 -200 
CI negative 150 1500 300 -200 
EI 150 N/A 1300 -70 
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041229_01 #446-458 RT: 6.89-6.99 AV: 13 SB: 177 4.83-5.59 , 6.28-7.02 NL: 4.82E6
T: + c CI Q1MS [50.00-500.00]





































124.7360.80 211.81 282.95242.89 406.87330.97 374.30 431.26 492.95
041229N_01 #440-458 RT: 6.82-6.98 AV: 19 SB: 177 4.84-5.59 , 6.27-7.00 NL: 5.85E4
T: - c CI Q1MS [50.00-500.00]



































218.03 287.94105.05 421.9378.80 352.09 479.68251.18 391.20
041227_01 #328-357 RT: 5.84-6.09 AV: 30 SB: 177 4.81-5.57 , 6.24-6.97 NL: 2.89E5
T: + c EI Q1MS [50.00-500.00]



































300.87 428.93110.95 341.85210.41 263.9661.76 369.15176.23 463.62 493.66
Figure 22   Acephate - Positive CI, Negative CI, EI spectra
50 
 
041229_02 #356 RT: 6.11 AV: 1 SB: 26 5.95-6.08 , 6.24-6.32 NL: 1.45E5
T: + c CI Q1MS [50.00-500.00]





































94.79 174.80 373.01123.92 211.50 293.05 425.50248.98 483.36
N/F 
041227_02 #358-360 RT: 6.10-6.12 AV: 3 SB: 26 5.93-6.06 , 6.21-6.29 NL: 3.00E4
T: + c EI Q1MS [50.00-500.00]




































268.93136.90 345.82165.95 218.1990.86 405.03 488.31431.02366.00
Figure 23   Azinphos Methyl - Positive CI, Negative CI, EI spectra
51 
 
041229_04 #577-579 RT: 8.04-8.06 AV: 3 NL: 2.79E6
T: + c CI Q1MS [50.00-500.00]










































041229N_04 #576-579 RT: 7.96-7.98 AV: 4 NL: 2.02E7
T: - c CI Q1MS [50.00-500.00]


































126.74 180.9294.72 240.9962.75 427.02285.83 390.13366.89 446.98313.10 498
041227_04 #576-578 RT: 7.95-7.97 AV: 3 SB: 26 5.93-6.06 , 6.21-6.29 NL: 5.87E7
T: + c EI Q1MS [50.00-500.00]









































236.88 363.00 452.01338.96278.91 419.60 4
Figure 24   Cadusafos - Positive CI, Negative CI, EI spectra 
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041229_05 #530-533 RT: 7.62-7.65 AV: 4 NL: 1.19E8
T: + c CI Q1MS [50.00-500.00]






































170.71 376.7096.63 488.73142.65 198.75 236.6464.78 416.75 446.67
041229N_05 #536-540 RT: 7.61-7.65 AV: 5 NL: 4.79E6
T: - c CI Q1MS [50.00-500.00]







































158.8073.78 370.84205.80126.74 336.86 420.96 471.63
041227_05 #538-540 RT: 7.63-7.64 AV: 3 SB: 14 7.51-7.56 , 7.70-7.75 NL: 3.02E7
T: + c EI Q1MS [50.00-500.00]











































Figure 25   Chlorethoxyfos - Positive CI, Negative CI, EI spectra 
53 
041229_06 #736-738 RT: 9.37-9.39 AV: 3 SB: 24 9.05-9.14 , 9.41-9.52 NL: 1.75E8
T: + c CI Q1MS [50.00-500.00]






































287.6696.63 257.62124.67 170.6464.76 437.69 469.85
041229N_06 #742-745 RT: 9.37-9.39 AV: 4 SB: 24 9.00-9.09 , 9.36-9.46 NL: 3.00E7
T: - c CI Q1MS [50.00-500.00]






































139.8278.73 192.80 248.84 385.89350.92 472.87408.80
041227_06 #743-746 RT: 9.37-9.40 AV: 4 SB: 24 9.00-9.08 , 9.35-9.45 NL: 1.68E7
T: + c EI Q1MS [50.00-500.00]














































Figure 26   Chlorpirifos - Positive CI, Negative CI, EI spectra 
54 
041229_07 #686 RT: 8.97 AV: 1 SB: 24 9.08-9.17 , 9.45-9.55 NL: 1.82E8
T: + c CI Q1MS [50.00-500.00]






































92.71 142.6278.72 447.69196.62 228.63 269.67 395.83 490.76
041229N_07 #694-698 RT: 8.95-8.99 AV: 5 SB: 24 8.99-9.08 , 9.35-9.45 NL: 2.10E7
T: - c CI Q1MS [50.00-500.00]






































320.86192.8096.75 248.8770.70 355.80 469.78391.08 447.68
041227_07 #694-697 RT: 8.95-8.98 AV: 4 SB: 24 9.00-9.08 , 9.35-9.46 NL: 2.59E7
T: + c EI Q1MS [50.00-500.00]





































167.63 270.68227.69 375.27 447.78418.41 470.23
Figure 27   Chlorpyrofos Methyl- Positive CI, Negative CI, EI spectra 
55 
041229_08 #1095 RT: 12.49 AV: 1 SB: 24 9.06-9.15 , 9.42-9.53 NL: 5.34E7
T: + c CI Q1MS [50.00-500.00]



































402.85328.81206.74 225.71138.72108.68 280.7864.79 180.73 429.10 450.46 493.16
041229N_08 #1110 RT: 12.49 AV: 1 SB: 24 9.00-9.09 , 9.36-9.46 NL: 2.23E7
T: - c CI Q1MS [50.00-500.00]




































328.02190.90126.75 297.97 377.06239.77 495.28451.7194.63 408.2776.69
041227_08 #1108 RT: 12.47 AV: 1 SB: 47 12.03-12.26 , 12.61-12.76 NL: 1.10E6
T: + c EI Q1MS [50.00-500.00]








































394.07 432.33 463.12 495.9
Figure 28   Coumaphos - Positive CI, Negative CI, EI spectra 
56 
041229_09 #634 RT: 8.48 AV: 1 SB: 94 7.82-8.28 , 8.65-8.98 NL: 2.35E8
T: + c CI Q1MS [50.00-500.00]







































151.78 247.76198.7692.72 456.96350.85 424.98 485.05
041229N_09 #636-638 RT: 8.46-8.48 AV: 3 SB: 94 7.79-8.24 , 8.61-8.94 NL: 3.65E7
T: - c CI Q1MS [50.00-500.00]


































126.73 275.01177.9794.75 303.09242.99 338.99 473.1278.65 362.01 451.90416.79
041227_09 #637 RT: 8.47 AV: 1 SB: 94 7.79-8.24 , 8.60-8.94 NL: 5.99E7
T: + c EI Q1MS [50.00-500.00]










































Figure 29   Diazinon - Positive CI, Negative CI, EI spectra 
57 
041229_10 #286 RT: 5.50 AV: 1 SB: 94 7.81-8.27 , 8.64-8.97 NL: 1.93E8
T: + c CI Q1MS [50.00-500.00]





































126.68 260.72 442.6978.71 328.71150.70 348.76 406.90 463.25
041229N_10 #284 RT: 5.47 AV: 1 SB: 94 7.79-8.24 , 8.61-8.94 NL: 1.41E6
T: - c CI Q1MS [50.00-500.00]




































78.79 204.85147.75110.70 390.28262.09 437.28358.01285.95
041227_10 #286 RT: 5.49 AV: 1 SB: 94 7.79-8.24 , 8.61-8.94 NL: 4.39E7
T: + c EI Q1MS [50.00-500.00]





































173.66 328.85234.85 266.79 384.13 437.15 478.00
Figure 30   Dichlorvos  - Positive CI, Negative CI, EI spectra 
58 
 
041229_11 #562-564 RT: 7.87-7.89 AV: 3 SB: 94 7.83-8.29 , 8.66-9.00 NL: 1.86E8
T: + c CI Q1MS [50.00-500.00]






































474.9771.77 154.71 348.90197.73 429.89308.86 391.99 479.32
041229N_11 #566-569 RT: 7.87-7.89 AV: 4 SB: 94 7.79-8.24 , 8.61-8.94 NL: 1.94E5
T: - c CI Q1MS [50.00-500.00]



































210.71146.8078.73 251.91 360.10305.10 430.29390.30 459.47 484.1
041227_11 #566-569 RT: 7.87-7.89 AV: 4 SB: 94 7.79-8.24 , 8.60-8.93 NL: 9.23E6
T: + c EI Q1MS [50.00-500.00]






































82.83 163.78 219.89 418.85268.27 326.78 450.12 478.90360.90
Figure 31   Dichrotophos - Positive CI, Negative CI, EI spectra  
59 
 
041229_12 #601-605 RT: 8.24-8.27 AV: 5 SB: 94 7.86-8.31 , 8.69-9.02 NL: 7.25E7
T: + c CI Q1MS [50.00-500.00]






































269.76142.63115.71 170.6673.78 458.81316.80 426.75399.77353.29 479.33
041229N_12 #608-614 RT: 8.23-8.28 AV: 7 SB: 94 7.79-8.24 , 8.61-8.94 NL: 2.37E7
T: - c CI Q1MS [50.00-500.00]


































126.74 385.93196.87102.72 355.88215.90 263.03 286.82 447.08 467.18
041227_12 #610-614 RT: 8.24-8.27 AV: 5 SB: 94 7.79-8.24 , 8.61-8.94 NL: 1.66E6
T: + c EI Q1MS [50.00-500.00]









































263.70 328.08 405.09 451.03348.51 487.90
Figure 32   Dimethoate - Positive CI, Negative CI, EI spectra 
60 
041229_13 #639-643 RT: 8.55-8.59 AV: 5 SB: 94 7.85-8.30 , 8.67-9.01 NL: 1.66E8
T: + c CI Q1MS [50.00-500.00]






































244.7096.64 124.6560.75 458.80 486.85426.80314.81 394.87
041229N_13 #647-650 RT: 8.56-8.59 AV: 4 SB: 94 7.80-8.25 , 8.61-8.94 NL: 1.30E7
T: - c CI Q1MS [50.00-500.00]


































126.73 206.94 244.89155.8294.7378.73 425.83375.90271.88 327.70 490.69449.54
041227_13 #646-650 RT: 8.55-8.58 AV: 5 SB: 94 7.79-8.24 , 8.61-8.94 NL: 3.13E7
T: + c EI Q1MS [50.00-500.00]











































311.97 408.18361.29 429.86 461.51
Figure 33   Disulfoton - Positive CI, Negative CI, EI spectra 
61 
 
041229_14 #871-875 RT: 10.55-10.59 AV: 5 SB: 94 7.84-8.30 , 8.67-9.01 NL: 1.75E8
T: + c CI Q1MS [50.00-500.00]







































170.65120.7096.65 366.81260.73 292.71 458.82 478.92
041229N_14 #881-887 RT: 10.55-10.60 AV: 7 SB: 94 7.79-8.24 , 8.61-8.94 NL: 5.29E7
T: - c CI Q1MS [50.00-500.00]


































126.73 354.89152.86 308.94 425.9194.78 198.91 229.8378.77 285.88 397.79 450.02 479.93
041227_14 #883-885 RT: 10.56-10.58 AV: 3 SB: 94 7.79-8.24 , 8.61-8.94 NL: 8.62E7
T: + c EI Q1MS [50.00-500.00]






































260.76 337.78292.73 404.84 449.97 480.72
Figure 34   Ethion - Positive CI, Negative CI, EI spectra 
62 
041229_15 #541-544 RT: 7.69-7.71 AV: 4 SB: 94 7.82-8.28 , 8.64-8.98 NL: 2.12E8
T: + c CI Q1MS [50.00-500.00]







































041229N_15 #544-548 RT: 7.68-7.72 AV: 5 SB: 94 7.79-8.24 , 8.61-8.94 NL: 2.48E7
T: - c CI Q1MS [50.00-500.00]


































126.75 166.8994.74 212.9262.69 336.98304.92247.90 399.04 453.99 480.98
041227_15 #545-547 RT: 7.69-7.71 AV: 3 SB: 94 7.79-8.24 , 8.61-8.94 NL: 5.49E7
T: + c EI Q1MS [50.00-500.00]








































213.80 354.85334.90 408.84280.87 441.01 464.01
Figure 35   Ethoprop   - Positive CI, Negative CI, EI spectra 
63 
041229_16 #738-742 RT: 9.39-9.43 AV: 5 SB: 94 7.83-8.29 , 8.66-8.99 NL: 1.81E8
T: + c CI Q1MS [50.00-500.00]





































136.71 235.70108.68 185.6664.75 427.84355.92 399.88 461.81 498.0
041229N_16 #744-749 RT: 9.38-9.42 AV: 6 SB: 94 7.79-8.24 , 8.61-8.94 NL: 4.71E7
T: - c CI Q1MS [50.00-500.00]




































137.83 261.93 319.02 460.06232.00107.80 181.82 430.04383.0678.66 492.23
041227_16 #745-749 RT: 9.38-9.42 AV: 5 SB: 94 7.79-8.24 , 8.60-8.93 NL: 2.95E7
T: + c EI Q1MS [50.00-500.00]








































308.06 408.27336.04 451.04 480.74
Figure 36   Ethyl Parathion - Positive CI, Negative CI, EI spectra 
64 
 
041229_17 #813 RT: 10.06 AV: 1 SB: 172 8.93-9.79 , 10.52-11.12 NL: 1.96E8
T: + c CI Q1MS [50.00-500.00]




































287.80261.78153.72 194.79121.7279.79 452.98360.92 390.98 498.0
041229N_17 #826-828 RT: 10.07-10.09 AV: 3 SB: 23 9.88-10.02 , 10.10-10.14 NL: 4.83E3
T: - c CI Q1MS [50.00-500.00]







































315.03 390.00192.80 229.83119.95 445.19367.08 423.11 480.08
041227_17 #827 RT: 10.08 AV: 1 SB: 172 8.85-9.70 , 10.41-11.01 NL: 8.94E7
T: + c EI Q1MS [50.00-500.00]








































108.77 310.19 422.51374.97 488.00464.39
Figure 37   Fenamiphos - Positive CI, Negative CI, EI spectra 
65 
 
041229_18 #716-719 RT: 9.21-9.23 AV: 4 SB: 23 9.96-10.10 , 10.18-10.23 NL: 2.15E8
T: + c CI Q1MS [50.00-500.00]





































124.65 231.7592.70 169.6978.70 385.78355.86 426.87 490.72
041229N_18 #722-726 RT: 9.20-9.23 AV: 5 SB: 23 9.88-10.02 , 10.10-10.15 NL: 5.30E7
T: - c CI Q1MS [50.00-500.00]




































261.92124.83 290.98 417.98230.94182.91 317.1893.84 477.18397.9957.60
041227_18 #723-726 RT: 9.20-9.23 AV: 4 SB: 23 9.88-10.01 , 10.10-10.14 NL: 2.31E7
T: + c EI Q1MS [50.00-500.00]







































181.77 291.96 369.02 417.72 448.98 491.90330.38
Figure 38   Fenitrothion - Positive CI, Negative CI, EI spectra  
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041229_19 #734-739 RT: 9.35-9.40 AV: 6 SB: 23 9.95-10.09 , 10.17-10.22 NL: 1.69E8
T: + c CI Q1MS [50.00-500.00]





































124.65 168.6992.7178.72 214.73 402.78370.82 446.82324.84 492.85
041229N_19 #741-746 RT: 9.36-9.40 AV: 6 SB: 16 9.28-9.33 , 9.43-9.50 NL: 4.12E4
T: - c CI Q1MS [50.00-500.00]




































152.88 276.8794.78 190.89 303.99229.9878.70 336.10 372.39 425.28
041227_19 #742-745 RT: 9.36-9.38 AV: 4 SB: 23 9.87-10.01 , 10.09-10.14 NL: 9.17E7
T: + c EI Q1MS [50.00-500.00]





































214.78 292.95 402.94369.24338.64 446.14 478.87
 Figure 39   Fenthion - Positive CI, Negative CI, EI spectra   
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041229_20 #735-739 RT: 9.34-9.37 AV: 5 SB: 16 9.31-9.36 , 9.46-9.53 NL: 5.32E5
T: + c CI Q1MS [50.00-500.00]




































246.8192.8268.84 138.80 201.91 359.21 404.59 434.78 466.89
041229N_20 #638 RT: 8.48 AV: 1 SB: 16 9.28-9.33 , 9.43-9.50 NL: 5.61E7
T: - c CI Q1MS [50.00-500.00]



































245.95136.85 216.9191.81 354.94 393.70309.89 472.20
041227_20 #637 RT: 8.46 AV: 1 SB: 16 9.27-9.32 , 9.42-9.49 NL: 3.69E7
T: + c EI Q1MS [50.00-500.00]






































429.03354.78 382.88281.93 326.95 450.02 491.80
 
Figure 40   Fonofos- Positive CI, Negative CI, EI spectra   
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041229_21 #723-727 RT: 9.24-9.27 AV: 5 SB: 16 9.32-9.37 , 9.47-9.54 NL: 1.34E8
T: + c CI Q1MS [50.00-500.00]







































158.65 256.7292.70 456.86216.8062.70 422.82 486.75384.84
041229N_21 #727-731 RT: 9.24-9.27 AV: 5 SB: 16 9.28-9.33 , 9.43-9.50 NL: 4.17E7
T: - c CI Q1MS [50.00-500.00]


































171.93126.74 242.94 314.99276.9397.81 199.95 369.80 389.9878.70 441.68 464.09
041227_21 #729 RT: 9.25 AV: 1 SB: 16 9.28-9.33 , 9.43-9.50 NL: 3.35E7
T: + c EI Q1MS [50.00-500.00]








































237.73183.73 329.86 422.87358.91 449.91 496.0
Figure 41   Malathion - Positive CI, Negative CI, EI spectra   
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041229_22 #298-311 RT: 5.60-5.71 AV: 14 SB: 16 9.31-9.36 , 9.47-9.53 NL: 4.24E7
T: + c CI Q1MS [50.00-500.00]




































92.73 282.74234.76195.84 314.99 415.01350.38 435.22 471.46
 
041229N_22 #228-240 RT: 5.00-5.10 AV: 13 SB: 79 4.56-4.85 , 5.26-5.62 NL: 2.17E4
T: - c CI Q1MS [50.00-500.00]



































287.98 344.28243.99 413.19168.00 180.8974.81 370.0090.89 452.05
 
041227_22 #297-336 RT: 5.58-5.91 AV: 40 SB: 79 4.56-4.85 , 5.26-5.63 NL: 8.24E5
T: + c EI Q1MS [50.00-500.00]






































300.85 428.92340.89280.93192.84146.88 404.93224.92 491.94
 
Figure 42   Methamidophos- Positive CI, Negative CI, EI spectra    
70 
041229_23 #804-807 RT: 9.92-9.95 AV: 4 SB: 79 4.57-4.86 , 5.27-5.63 NL: 1.37E8
T: + c CI Q1MS [50.00-500.00]



































330.7384.73 446.75270.67242.71124.65 170.6357.77 210.69 342.75 386.77 426.69 472.62
041229_23 #804-807 RT: 9.92-9.95 AV: 4 SB: 79 4.57-4.86 , 5.27-5.63 NL: 1.37E8
T: + c CI Q1MS [50.00-500.00]



































330.7384.73 446.75270.67242.71124.65 170.6357.77 210.69 342.75 386.77 426.69 472.62
041227_23 #807-810 RT: 9.91-9.93 AV: 4 SB: 79 4.56-4.85 , 5.26-5.62 NL: 7.36E6
T: + c EI Q1MS [50.00-500.00]






































156.6994.68 206.85 270.72 314.62 340.97 388.81 465.13408.09 493.8
Figure 43   Methidathion - Positive CI, Negative CI, EI spectra 
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041229_24 #694-698 RT: 8.97-9.01 AV: 5 SB: 79 4.57-4.86 , 5.26-5.63 NL: 1.84E8
T: + c CI Q1MS [50.00-500.00]






































217.72155.6878.71 371.78 496.8341.81 398.81 462.85
041229N_24 #694-700 RT: 8.96-9.01 AV: 7 SB: 79 4.57-4.86 , 5.26-5.63 NL: 3.07E7
T: - c CI Q1MS [50.00-500.00]




































247.87126.74 276.95215.89 403.97178.9393.75 345.07 452.02 476.01
041227_24 #697-700 RT: 8.97-9.00 AV: 4 SB: 79 4.56-4.85 , 5.25-5.62 NL: 2.48E7
T: + c EI Q1MS [50.00-500.00]






































167.76 280.93 316.74 374.96 451.13407.04 482.97
Figure 44   Methyl parathion - Positive CI, Negative CI, EI spectra   
72 
 
041229_25 #411-415 RT: 6.56-6.59 AV: 5 SB: 79 4.57-4.86 , 5.27-5.63 NL: 1.75E8
T: + c CI Q1MS [50.00-500.00]






































448.89154.71 350.8094.72 416.84322.85 489.07
041229N_25 #412-414 RT: 6.56-6.58 AV: 3 SB: 79 4.57-4.86 , 5.26-5.63 NL: 3.27E7
T: - c CI Q1MS [50.00-500.00]


































177.89138.90 218.90 348.9998.7978.77 250.97 285.94 390.18 417.69 466.28
041227_25 #412-415 RT: 6.56-6.58 AV: 4 SB: 79 4.57-4.85 , 5.26-5.63 NL: 4.67E7
T: + c EI Q1MS [50.00-500.00]







































234.91 374.95342.81285.36 404.99 461.20 481.09
Figure 45 Mevinphos - Positive CI, Negative CI, EI spectra   
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041229N_26 #562-566 RT: 7.84-7.87 AV: 5 SB: 79 4.56-4.85 , 5.26-5.63 NL: 7.05E6
T: - c CI Q1MS [50.00-500.00]








































169.79 344.72262.86 460.72218.8197.70 414.71 485.03
041227_26 #563-566 RT: 7.83-7.86 AV: 4 SB: 79 4.56-4.85 , 5.25-5.62 NL: 1.52E6
T: + c EI Q1MS [50.00-500.00]







































59.86 218.78 254.68 313.06 405.98344.82 450.96 480.95
041229_26 #562-565 RT: 7.84-7.86 AV: 4 SB: 79 4.56-4.85 , 5.26-5.62 NL: 2.08E7
T: + c CI Q1MS [50.00-500.00]












































82.67 408.57328.66 442.67 486.68
Figure 46 Naled - Positive CI, Negative CI, EI spectra   
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041229_27 #206 RT: 4.81 AV: 1 SB: 79 4.57-4.86 , 5.26-5.63 NL: 2.94E7
T: + c CI Q1MS [50.00-500.00]




































142.66108.67 208.7466.78 336.79292.82259.04 391.11 479.28429.17
041229N_27 #193-203 RT: 4.70-4.78 AV: 11 SB: 79 4.56-4.85 , 5.26-5.62 NL: 1.76E4
T: - c CI Q1MS [50.00-500.00]



































250.70 285.87152.6990.65 210.81 338.09 390.17
041227_27 #204 RT: 4.79 AV: 1 SB: 79 4.56-4.85 , 5.26-5.62 NL: 1.98E6
T: + c EI Q1MS [50.00-500.00]






































356.11266.86 391.40196.99 324.35 452.91241.90 478.17
Figure 47   Oxydemethon methyl - Positive CI, Negative CI, EI spectra   
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041229_28 #584-586 RT: 8.02-8.03 AV: 3 NL: 1.75E8
T: + c CI Q1MS [50.00-500.00]





























230.6976.74 300.78120.70 170.64 412.80 458.8096.63 380.82288.79 320.75 477.79360.71
041229N_28 #583-586 RT: 8.01-8.04 AV: 4 NL: 2.54E7
T: - c CI Q1MS [50.00-500.00]
























126.74 192.89 230.88152.85110.7176.80 286.03 425.88324.85 390.29 451.99355.71 485.48
041227_28 #584-586 RT: 8.02-8.03 AV: 3 NL: 6.20E7
T: + c EI Q1MS [50.00-500.00]






























262.81 380.93334.95292.73 412.73 462.80 478.99
Figure 48   Phorate - Positive CI, Negative CI, EI spectra   
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041229_29 #1013 RT: 11.68 AV: 1 NL: 4.02E7
T: + c CI Q1MS [50.00-500.00]









































371.76211.74169.67 307.75 409.79120.7174.85 221.74 339.6896.66 137.69 372.78280.80268.78 441.77 487.84453.05
041229N_29 #1015 RT: 11.68 AV: 1 NL: 5.98E7
T: - c CI Q1MS [50.00-500.00]



































187.76 366.97184.09 302.94126.73 213.91152.80 401.99337.94110.6878.62 432.59242.09 457.00259.00
041227_29 #1014-1017 RT: 11.67-11.69 AV: 4 NL: 3.07E6
T: + c EI Q1MS [50.00-500.00]





























198.7564.86 369.82280.83213.81 321.76252.88 340.83 404.98 428.72 464.99 489.2
Figure 49   Phosalone - Positive CI, Negative CI, EI spectra   
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041229_30 #974 RT: 11.34 AV: 1 SB: 162 10.41-11.23 , 11.49-12.04 NL: 9.72E6
T: + c CI Q1MS [50.00-500.00]


























318.77285.73124.65 357.76162.76 201.74104.81 271.94 476.93390.90 423.35
041229N_30 #975 RT: 11.34 AV: 1 SB: 165 10.41-11.23 , 11.49-12.05 NL: 2.40E7
T: - c CI Q1MS [50.00-500.00]

























146.87 192.89 284.99 316.87 369.57252.7294.86 451.9875.70 388.09
041227_30 #583 RT: 8.01 AV: 1 SB: 165 10.41-11.23 , 11.49-12.05 NL: 1.11E7
T: + c EI Q1MS [50.00-500.00]

























193.80 260.08 477.54351.87 371.12 419.00325.52
Figure 50   Phosmet - Positive CI, Negative CI, EI spectra   
78 
 
041229_31 #659 RT: 8.65 AV: 1 SB: 164 10.40-11.23 , 11.48-12.05 NL: 1.30E8
T: + c CI Q1MS [50.00-500.00]





























041229N_30 #974 RT: 11.33 AV: 1 SB: 165 10.41-11.23 , 11.49-12.05 NL: 1.32E7
T: - c CI Q1MS [50.00-500.00]

























146.87 192.91 284.97 317.03238.82110.64 369.71 390.2878.98
041227_31 #660 RT: 8.66 AV: 1 SB: 165 10.40-11.24 , 11.49-12.04 NL: 5.87E7
T: + c EI Q1MS [50.00-500.00]






























321.91 359.66 422.95 442.84 475.76
Figure 51   Phostebupirim - Positive CI, Negative CI, EI spectra   
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041229_32 #718-723 RT: 9.15-9.20 AV: 6 NL: 1.44E8
T: + c CI Q1MS [50.00-500.00]



























163.78 261.77232.74124.6492.7154.79 195.81 429.86397.92359.91 468.02 484.9
041229N_32 #718-723 RT: 9.16-9.21 AV: 6 NL: 3.27E5
T: - c CI Q1MS [50.00-500.00]

























199.97 291.05146.83107.7792.82 275.08244.83 324.38 360.99 420.29 454.28378.31
041227_32 #719-723 RT: 9.16-9.19 AV: 5 NL: 3.65E7
T: + c EI Q1MS [50.00-500.00]































317.93 341.04 429.89 451.04400.91 479.05
Figure 52   Pirimphos methyl - Positive CI, Negative CI, EI spectra 
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041229_33 #836-840 RT: 10.16-10.19 AV: 5 NL: 1.15E8
T: + c CI Q1MS [50.00-500.00]




























332.63138.67 207.61 266.6596.63 231.6662.78 460.90421.09 498.7
041229N_33 #834-840 RT: 10.15-10.20 AV: 7 NL: 8.67E6
T: - c CI Q1MS [50.00-500.00]




























250.89 344.87 373.92139.81 408.88116.67 452.8578.13 213.88165.84 470.81
041227_33 #836-839 RT: 10.16-10.18 AV: 4 NL: 1.16E7
T: + c EI Q1MS [50.00-500.00]
































98.7174.82 251.69 344.71 422.29388.76 450.94 480.81
Figure 53   Profenofos - Positive CI, Negative CI, EI spectra   
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041229_34 #626-629 RT: 8.37-8.40 AV: 4 NL: 1.31E8
T: + c CI Q1MS [50.00-500.00]
































041229N_34 #624-628 RT: 8.36-8.40 AV: 5 NL: 4.82E7
T: - c CI Q1MS [50.00-500.00]

























193.86126.77 281.0199.79 308.98220.9783.82 264.96 407.81370.98336.94 451.81 498.8
041227_34 #625-628 RT: 8.37-8.39 AV: 4 NL: 3.33E7
T: + c EI Q1MS [50.00-500.00]





























280.87 324.97 369.21 408.07 451.05 479.14
Figure 54   Propetamphos - Positive CI, Negative CI, EI spectra   
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041229_35 #571-575 RT: 7.91-7.94 AV: 5 NL: 1.68E8
T: + c CI Q1MS [50.00-500.00]



























201.68170.70 244.7396.67 120.7164.80 442.88 474.89384.79 416.78
041229N_35 #572-573 RT: 7.92-7.93 AV: 2 SB: 13 7.83-7.89 , 7.96-7.99 NL: 2.27E4
T: - c CI Q1MS [50.00-500.00]





























78.75 231.93192.95 262.92 363.78110.59 452.78390.17
041227_35 #574 RT: 7.93 AV: 1 NL: 9.59E7
T: + c EI Q1MS [50.00-500.00]






























80.71 353.86 384.97 475.07407.26 442.28
Figure 55   Sulfotepp - Positive CI, Negative CI, EI spectra  
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041229_37 #629-633 RT: 8.40-8.43 AV: 5 SB: 13 7.82-7.88 , 7.95-7.98 NL: 1.49E8
T: + c CI Q1MS [50.00-500.00]




























152.6874.74 124.65 362.82 440.82306.73 486.85408.85
041229N_37 #628-632 RT: 8.40-8.43 AV: 5 SB: 13 7.83-7.89 , 7.95-7.99 NL: 1.78E7
T: - c CI Q1MS [50.00-500.00]
























126.74 152.87 258.94110.70 192.9076.72 288.75 425.90375.89310.81 452.99357.99
041227_37 #630-633 RT: 8.41-8.43 AV: 4 SB: 13 7.82-7.88 , 7.95-7.98 NL: 9.57E7
T: + c EI Q1MS [50.00-500.00]






























78.72 272.89 334.93 409.01385.02300.91 493.09432.84
Figure 56   Terbufos - Positive CI, Negative CI, EI spectra  
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041229_38 #813-815 RT: 9.96-9.98 AV: 3 SB: 13 7.83-7.88 , 7.95-7.99 NL: 3.80E7
T: + c CI Q1MS [50.00-500.00]




























406.68154.71108.66 206.63 268.64 492.7178.70 166.67 300.64 358.74 474.75419.07
041229N_38 #811-816 RT: 9.95-9.99 AV: 6 SB: 13 7.83-7.88 , 7.95-7.99 NL: 4.05E7
T: - c CI Q1MS [50.00-500.00]
























241.84221.87110.78 138.86 277.87 490.92329.91 350.8678.72 187.84 380.87 451.88418.19
041227_38 #813-815 RT: 9.96-9.98 AV: 3 SB: 13 7.82-7.88 , 7.95-7.99 NL: 3.53E6
T: + c EI Q1MS [50.00-500.00]


























203.6878.80 228.75 365.71156.69132.72 313.73265.82 450.81402.08 479.01
Figure 57   Tetrachlorvinphos - Positive CI, Negative CI, EI spectra   
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041229_39 #836-840 RT: 10.16-10.20 AV: 5 SB: 13 7.83-7.89 , 7.95-7.99 NL: 1.60E8
T: + c CI Q1MS [50.00-500.00]




























270.76102.7288.73 482.88176.74 370.92 416.94 450.91
041229N_39 #834-840 RT: 10.15-10.20 AV: 7 SB: 13 7.83-7.89 , 7.96-7.99 NL: 6.26E7
T: - c CI Q1MS [50.00-500.00]
























224.97167.82135.83 270.98110.68 200.8278.73 392.98293.84 425.05336.79 451.90 470.68361.09
041227_39 #837-840 RT: 10.17-10.19 AV: 4 SB: 13 7.82-7.88 , 7.95-7.98 NL: 2.70E7
T: + c EI Q1MS [50.00-500.00]


































57.89 176.81 284.92 422.20376.90326.87 448.92 475.16
Figure 58   Tribufos - Positive CI, Negative CI, EI spectra   
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041229_40 #836-837 RT: 10.16-10.16 AV: 2 SB: 73 7.22-7.47 , 7.86-8.21 NL: 1.07E7
T: + c CI Q1MS [50.00-500.00]



























298.82 354.8856.81 257.74201.66144.79102.71 391.03 437.87 483.05
041229N_40 #835 RT: 10.16 AV: 1 SB: 74 7.22-7.47 , 7.85-8.21 NL: 4.03E7
T: - c CI Q1MS [50.00-500.00]


























041227_40 #837 RT: 10.16 AV: 1 SB: 73 7.22-7.47 , 7.86-8.21 NL: 1.49E6
T: + c EI Q1MS [50.00-500.00]
































Figure 59   Trichlorfon - Positive CI, Negative CI, EI spectra   
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CHAPTER 3: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY – 
MASS SPECTROMETRY 
Many of the analytes are thermally labile, highly polar or otherwise unsuitable for GC 
separations. Examples are methamidophos, acephate, and azinphos methyl. These 
compounds are the candidates for HPLC separations and form the core of the LC group 
of compounds. Other analytes were added because after preliminary experiments it was 
determined that they likely have a better LOD in an LC-MS-MS method. 
In the HPLC-MS-MS system two ionization modes were available: electrospray 
ionization (ESI) and atmospheric pressure chemical ionization (APCI), positive or 
negative polarity for each. The feasibility of ionization modes and polarizations were 
tested by injecting concentrated (approximately 5 μg/mL samples into a rapid HPLC 
eluent gradient and observing full scan spectra, using only a single quadropole of the 
mass spectrometer. This process was repeated for all four combinations of ionization 
modes in both polarities. All forty of the analytes were tested, because at this point it was 
unclear weather or not all OP pesticides can be analyzed solely on a HPLC-MS-MS 
system.  
As it is apparent by looking at the ionization tables (Table 13) that more  compounds 
ionize in APCI mode than in ESI mode. The reason is that ESI ionization takes place in 
the solution phase, while the APCI ionization happens in the plasma surrounding the 
charged needle. When one has to choose between positive and negative ionization, - 
especially when studying biological, dirty samples – negative ionization has an 
advantage. If the analyte of interest is ionizing in the negative mode, the background is 
often lower. The reason is that in the majority of cases positive ionization requires 
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addition of a proton, while negative ionization needs the removal of one. It is easier to 
add a proton from some external source than find an already existing proton to lose.  
 
  Mono Ions (m/z), nominal amu 
  isotopic ESI APCI 
No. OP Mass Positive Negative Positive Negative 
1 Acephate 183.012 184 182 184 168 
2 Azinphos-methyl 317.006 318   318 157 
3 Bensulide 397.061 398 396 442 356, 398 213 
4 Cadusafos* 270.088 271, 541 426 271, 541 213 
5 Chlorethoxyfos 333.892       
305, 307, 
309 





methyl 320.895 115, 143,  306 308 321 
212, 214 
216 
8 Coumaphos 362.014 363   363 
225, 208, 
333 
9 Diazinon 304.101 305  169 215 305 169, 215 
10 
Dichlorvos 
(DDVP) 219.946 262 264 205 207 262, 253 205, 207 
11 Dicrotophos 237.077 475 223 291 709 270, 283 171 
12 Dimethoate 230.000 230, 459 274 230 157 
13 Disulfoton 274.028 305 185 363 185 
14 Ethion 383.988 385   385 185 
15 Ethoprop 242.560 485 213 243, 485 199 
16 Ethyl parathion 291.033 173, 243, 305   262 
262, 154, 
138 
17 Fenamiphos 271.134     304, 363, 607 247 
18 Fenitrothion 277.017 305 115 262 383 
124, 165, 
248, 289 168 
19 Fenthion 278.020 342 263 279, 311, 320 263 
20 Fonofos** 246.030 247, 173 137 247 169 
21 Malathion 330.036 331 315 331 157 
Table 13   Table of LC-MS ions in APCI and ESI mode, positive or negative ionization  Bolded ions ara the most aboundant 





  Mono Ion Masses 
  isotopic ESI APCI 
No. OP Mass Positive Negative Positive Negative 
22 Methamidophos 141.001 142, 283 141 187  283, 174, 142   
23 Methidathion 301.962 303 366 248 287 303 157 
24 Methyl parathion 263.002 115 
277 138 248 
325 151, 234, 275 248, 154 
25 Mevinphos* 224.045 225 449 209 255 225, 257 
171, 125, 
237 





methyl 246.015 247 231 247 141 
28 Phorate 260.013 335 115 143 185 231 355 261, 335 185 
29 Phosalone* 366.986 368 167 368 185 
30 Phosmet 316.995     318 157 
31 Phostebupirim 318.117 319   319 275 
32 Pirimiphos methyl 305.096  318, 381 290 306 
141, 290 
187 
33 Profenofos 371.935  306 
313 315, 317 
343 345 347 373 405, 407 
343, 345, 
347 
34 Propetamphos 281.085 282    282…327 
154, 280, 
200 
35 Sulfotepp 322.023     323 
169, 293, 
155 
36 Temephos 465.990   451 467 451, 141 







397..399… 171, 125 
39 Tribufos (DEF) 314.096 315   315, 347, 629 257 
40 Trichlorfon 255.923 257… 515 301 303 305
143, 152, 
221, 257, 289   
Table 13    Table of LC-MS ions in ESI and APCI mode, positive or negative Bolded ions ara the most 
aboundant (Weak)  ionization (cont. from previous page) 
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Liquid Chromatography: HPLC 
After deciding an ionization mode the next step is to develop the analytical separation 
part of the method  
In the literature the commonly used column type for the analytical separation of OP 
pesticides is the reversed phase C-18. [26-28] For this reason we started with variants of 
C-18 columns: betasil C18, Aquasil C18. Hydrophilic – hydrophobic properties of our 
compounds of interest vary widely as it was observed in the introduction. Compounds 
like acephate and methamidophos are extremely water soluble, do not retain very well on 
most packing. Very lipophilic, oily OP pesticides, such as Tribufos on the other hand; 
have very good retention. 
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Size End-   
    [mm] [mm] [µm] Load   cap       
Aquasil C18 Thermo 100 4.6 5 12% 100 A Yes 
High purity,base 
deactivated C18 
Betasil C8 Thermo 100 4.6 5 12% 100 A Yes 
High purity,base 
deactivated C8 
Betasil C18 Thermo 100 4.6, & 2.1 5 20% 100 A Yes 
High purity,base 
deactivated C18 






Sciences 100 4.6 5 17% 120 A Yes 
High purity silica 
gel C18 
Discovery HS F5 Supelco 100 4.6 3 12% 120 A Yes 
silica gel, high 
purity, spherical 
particle platform 
Pentafluorophenyl propyl  
 
Fluorphase RP Thermo 50 2.1 5 10% 100 A Yes 
High purity,base 
deactivated perfluorinated C6 
Prism RP Thermo 50 2.1 5 12% 100 A Yes 
High purity,base 
deactivated Urea+ C12 chain 
Zorbax SB C3 Agilent 100 4.6 5 4% 80 A No  Diisopropyl propyl 




Using the C-18 type columns , it became apparent that when applying linear – or close 
to linear – elution curves, that the compounds separate into two groups: early and late 
eluting compounds. Many of the experiments listed in tables 15-17 were attempts to 
further resolve these two elution groups to their components. While it is not absolutely 
necessary when using tandem mass spectrometer as detector, resolving peaks can help by 
eliminating possible interferents and, ion competition. If many analytes elute very 
closely, it can complicate the instrument method setup. Since the MS has to spend a finite 
amount of time on each transition, in the presence of many overlapping peaks the number 
of data points for each peak may be limited.  
An other aspect of the overlapping peaks is the signal to noise ratio. The detector 
works in ion counting mode, so when the time to collect ion counts is limited – 
background being the same- the signal to noise ratio worsens. So even in with the 
resolving power of tandem mass spectrometry, good chromatographic resolution provides 
an advantage. 
 
Selection of eluents.  
Before developing the analytical separations part of the method, the detection was 
decided to be APCI, positive ionization. The selection of ionization mode has a major 
influence on the on the selection of solvents, sizing of the column and picking the right 
flow rate. The two most often used combination of eluents are: water-methanol and 
water-acetonitrile.  
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Figure 60   Viscosity profiles of Methanol - Water and Acetonitrile - Water blends, according to Thompson 
[34] 
One of the practical differences between the two pairs is that the water - methanol 
gradient has a viscosity maximum while the water – acetonitrile mixture does not.  
Acetonitrile and methanol gives different retention times.  
Another difference between the two solvents is the propensity to form adducts. From 
previous work we saw that both solvents tend to form adducts with many of the analytes. 
Polarity of ionization makes a difference: acetonitrile is more likely to form adducts in 
positive ionization while methanol adducts are favored in negative ionization. 
 
 The TSQ Quantum-s APCI probe can be operated between .2 and 2 mL/min, the 
recommended optimum being approximately 1mL/min. This flow rate will work well 
with a 4.6 mm internal diameter column. Smaller diameter columns may be – and were – 
tried, but the increased pressure leads to leaks and sometimes clogging. In this method 
real life samples, with varying degree of purity have to be run reliably. The 4.6mm 
internal diameter, 100mm length combined with 1.0 mL/min flow rate proved to be the 
most useful combination.  
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  Betasil   Betasil   Betasil  
  C18  C18  Phenyl  
  Width: 2.1mm  4.6mm  4.6mm 4.6mm 
No. OP Length: 100mm   100mm   MeOH ACN 
1 Acephate 8.1  7.94  6.15 5.62  
2 Azinphos-methyl 21.83  19.35  20.53 17.11  
3 Bensulide 24.2  21.4  21.72 19.08  
4 Cadusafos* 25.64  22.39  21.05 17.59  
5 Chlorethoxyfos 26.88   -   N/F N/F E/B 
6 Chlorpyrifos 27.41  23.5  22.53 28.06 E/B 
7 Chlorpyrifos methyl 25.86  22.57  21.67 27.61 E/B 
8 Coumaphos 24.85  21.88  22.24 19.15  
9 Diazinon 24.8  21.83  21.18 17.92  
10 Dichlorvos (DDVP) 19.08   16.72   15.67 N/F E/B 
11 Dicrotophos 14.25  12.13  13.68 9.94  
12 Dimethoate 15.71  14.29  14.16 11.68  
13 Disulfoton 28.94  22.43  21.66 N/F  
14 Ethion 26.97  23.19  23.1 20.58  
15 Ethoprop 23.72   21.08   19.86 16.28   
16 Ethyl parathion 24.46  21.62  21.09 N/F E/B 
17 Fenamiphos 24.19  21.42  20.77 16.5  
18 Fenitrothion 23.36  20.76  20.64 N/F E/B 
19 Fenthion 24.83  21.9  21.82 N/F E/B 
20 Fonofos** 24.91   21.98   21.25 18.85   
21 Malathion 22.97  20.41  20.57 17.89  
22 Methamidophos 4.08  6.43  3.67 3.47  
23 Methidathion 21.66  19.18  19.75 16.86  
24 Methyl parathion 22.46  19.98  19.66 N/F E/B 
25 Mevinphos* 16.97   15.14   15.18 11.72   
26 Naled 21.52  18.96  18.47 N/F  
27 Oxydemeton methyl 12.79  10.67  12.34 10.22 split 
28 Phorate 25.4  22.27  21.29 N/F E/B 
29 Phosalone* 25.26  22.17  22.12 N/F E/B 
30 Phosmet 29.03   N/F   N/F N/F E/B 
31 Phostebupirim 26.79  23.13  22.04 19.27  
32 Pirimiphos methyl 24.72  21.71  20.69 17.56  
33 Profenofos 26.4  22.86  22 N/F E/B 
34 Propetamphos 23.21  20.64  19.87 17.68  
35 Sulfotepp 24.56   21.67   21.31 19.11   
36 Temephos 26.73  22.98  24.04 N/F E/B 
37 Terbufos 26.75  23.09  22.15 N/F  
38 Tetrachlorvinphos 24.28  21.51  21.03 17.53  
39 Tribufos (DEF) 28.58  24.31  23.17 20.08  
40 Trichlorfon 19.09   16.73   15.64 N/F E/B 
 
 Table 15   Retenetion times of OP pesticides on Betasil C18 and Phenyl Columns (N/F: not found, E/B: 
extreme peak broadening) 
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   Aquasil C18 Chromolith RP 18e Zorbax SBC3 
  Width:   4.6mm  4.6mm   4.6mm  
No. OP Length:    100 mm   100 mm   100 mm  
1 Acephate  8.35  7.33  7.53 
poor 
peakshape 
2 Azinphos-methyl  20.12  18.42  19.43  
3 Bensulide  21.56  21.19  21.19  
4 Cadusafos*  22.76  22.51  22.19  
5 Chlorethoxyfos   20.1 Poor peak     N/F    N/F   
6 Chlorpyrifos  23.63  23.79  22.65  
7 Chlorpyrifos methyl  22.77 Poor peak 22.61  21.63  
8 Coumaphos  22.57  21.8  22.29  
9 Diazinon  22.32  21.67  21.75  
10 Dichlorvos (DDVP)   16.77   15.79   16.24   
11 Dicrotophos  13.8  11.73  14.13  
12 Dimethoate  14.12  12.42  14  
13 Disulfoton  22.47 Bad tailing 22.39 Smearing 21.4  
14 Ethion  23.55  23.59  22.58  
15 Ethoprop   21.45   20.39   20.63   
16 Ethyl parathion  21.86  21.25  20.97  
17 Fenamiphos  21.79  21.05  20.93  
18 Fenitrothion  21.04  19.91  20.15  
19 Fenthion  22.23  21.66  21.01  
20 Fonofos**   22.1   21.65   20.92   
21 Malathion  20.45  19.52  20.01  




23 Methidathion  19.26  18.08  18.86  
24 Methyl parathion  20.06  18.88  19.21  
25 Mevinphos*   15.26   13.96   15.91   
26 Naled  *  18.06   N/F  
27 Oxydemeton methyl  12.79  10.39  12.38  
28 Phorate  22.35  22.14  21.13  
29 Phosalone*  22.41  22.17  21.64  
30 Phosmet    N/F    N/F    N/F   
31 Phostebupirim  23.26  23.38  22.48  
32 Pirimiphos methyl  21.87  20.85  20.77  
33 Profenofos  23.31  23.14  22.29  
34 Propetamphos  20.64  19.79  20.07  
35 Sulfotepp   21.71   21.43   20.86   
36 Temephos  23.47  23.55  22.78  
37 Terbufos  23.17  23.33  22.23  
38 Tetrachlorvinphos  21.88  21.15  20.9  
39 Tribufos (DEF)  24.31  24.51  23.6  
40 Trichlorfon   15.27   14.17   15.88   
 
 Table 16   Retenetion times of OP pesticides on Aquasil C18 and Chromolit RP 18e, Zorbax SBC3 
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 Discovery HS F5 3µm Hypercarb Varian C18 
 Width:  4.6mm   4.6mm  4.6mm  
No. OP Length:  100 mm   100 mm   250mm    
1 Acephate 7.61  3.22  12.74  
2 Azinphos-methyl 20.61  N/F E/B 23.99  
3 Bensulide 22.21  22.62 tailing 24.65  
4 Cadusafos* 21.7  18.73  26.17  
5 Chlorethoxyfos N/F   N/F E/B N/F   
6 Chlorpyrifos 22.85  N/F E/B 27.53  
7 Chlorpyrifos methyl 22.12  N/F E/B N/F E/B 
8 Coumaphos 23.83  N/F E/B 25.62  
9 Diazinon 22.4  21.05  25.77  
10 Dichlorvos (DDVP) 16.8   N/F E/B 21.64   
11 Dicrotophos 13.39  9.33  16.69  
12 Dimethoate 14.86  10.46  18.43  
13 Disulfoton N/F  N/F  26.21  
14 Ethion 23.31  25.26 tailing 26.8  
15 Ethoprop 19.98   15.63   24.98   
16 Ethyl parathion 22.75  N/F E/B 25.28  
17 Fenamiphos 20.97  N/F E/B 24.88  
18 Fenitrothion 22.1  N/F E/B 24.7  
19 Fenthion 21.99  N/F E/B 25.77  
20 Fonofos** 22.02   8.23   25.92   
21 Malathion 21.27  18.7  24.23  
22 Methamidophos 4.28  1.43  12  
23 Methidathion 20.4  22.03  23.74  
24 Methyl parathion 21.57  N/F E/B 24.13  
25 Mevinphos* 15.59   N/F E/B 19.41   
26 Naled 18.55  N/F  N/F  
27 Oxydemeton methyl 11.57  8.23  15.35  
28 Phorate 22.02 tailing N/F  26.9  
29 Phosalone* 22.57  N/F  25.66  
30 Phosmet N/F   N/F E/B N/F   
31 Phostebupirim 22.73  20.45  27  
32 Pirimiphos methyl 26.26  N/F E/B 25.89  
33 Profenofos 22.25  N/F E/B 26.72  
34 Propetamphos 20.6  17.76  24.26  
35 Sulfotepp 21.92   17.32   25.21   
36 Temephos 23.59  N/F E/B 26.44  
37 Terbufos 22.96  N/F  26.87  
38 Tetrachlorvinphos 21.19  N/F E/B 25.09  
39 Tribufos (DEF) 23.01  N/F  28.5  
40 Trichlorfon 16.82   N/F E/B 19.38   
 
 Table 17   Retenetion times of OP pesticides on Discovery HS F5, Hyper carb and Varian C18 columns 
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Figure 61   Betasi C18 and Betasil Phenyl retention profile using a linear water methanol gradient 
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Betasil Phenyl, final gradient  (GC group is grayed out) 
Figure 62   Aquasil C18 retention profile using a linear water methanol gradient and Betasil Phenyl using the final, non lina=ear solvent gradient   
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Alternative to the one column HPLC separation 
For sake of simplicity, as mentioned earlier, a single column, the 4.6X100mm Betasil 
Phenyl column was selected. This column did not resolve all the compounds in the late 
eluting group, but with the modified gradient gave sufficient separation. The reason for 
this is the same as the core difficulty of our problem: we have to deal with a very large 
group of compounds. It is difficult if not impossible to find one single column that will 
separate all the analytes in an even manner. 
An alternative is to use two columns and create a “two dimensional system”, where 
one column separates the early eluting group but not the late eluting ones. This late group 
then directed on a different type of column, where it is separated with a more organic rich 
gradient. It would be recommended to use Aquasil C18 or Betasil Phenyl for first column 
and Discovery HF S5 as a second column.  
This system can be achieved with two properly timed six port valves. As it is 
illustrated in Figure 63 
100 
 
Figure 63   Two column HPLC system. 1: Column A separates the first analyte group. 2: The group of 
unresolved analytes pass column A and  are loaded onto column B.  3: This second group of analytes are 
gradient eluted and separated on column B. 
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CHAPTER 3   APPENDIX 
Appendix 3A APCI  Source Temperature Studies 
 
Because many of the OP pesticides known to be thermally labile, an investigation was 
undertaken to study the effect of source temperature on on signal strength. 
In APCI, source temperature has two components:  
• Evaporator temperature is the temperature of the porcelain tube where the LC 
solvent stream enters in the source. This is where the liquid eluent starts to 
evaporate and forms an aerosol with the nitrogen sheet gas. Evaporator 
temperature may be raised up to 600°C.  
• Capillary or “ion transfer tube” temperature may be adjusted between 0 and 400°. 
The capillary is the narrow ion guide that separates the atmospheric part of the 
APCI source from the first stage of vacuum. Its temperature is important 
optimization factor because this is where the last traces of water is dried off, or 
where the dehydratation of the ions is completed.  
Too low temperature will result in incomplete drying, too high temperature causes 
thermal decomposition. 
While both temperatures may be adjusted, neither one of them is suitable to change 
during a run. A pair of compromise temperatures have to be found to accommodate 
all the analytes. 
102 
The following set of charts illustrates the effect of these temperature combinations for 
all analytes. 350 °C for evaporator temperature and 250°C capillary temperature was 
found to be the best combination for the analytes selected for HPLC MS-MS. 
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12
Area Count/1000 150 250 400
VAP 250 1.4 1.5 0.3
Vaporizer VAP 350 2.2 1.6 0.3
VAP 450 2 1.4 0.19
Vaporizer - Heated Capillary Temperature Effect
13
Area Count/1000 150 250 400
VAP 250 0.015 0.014 0
Vaporizer VAP 350 0.045 0 0






















































Area Count/1000 150 250 400
VAP 250 0.74 0.12 0
Vaporizer VAP 350 0.85 0.07 0
VAP 450 0.45 0.01 0
4
Area Count/1000 150 250 400
VAP 250 3.4 2.5 0
Vaporizer VAP 350 3.4 1.7 0

























































Area Count/1000 150 250 400
VAP 250 0 0 0
Vaporizer VAP 350 0 0 0.001327
VAP 450 0 0 0.007349
6
Area Count/1000 150 250 400
VAP 250 0.003 0.26 0.29
Vaporizer VAP 350 0.022 0.58 0.34

























































Area Count/1000 150 250 400
VAP 250 0 0.002 0.062
Vaporizer VAP 350 0 0.03 0.11
VAP 450 0 0.068 0.093
8
Area Count/1000 150 250 400
VAP 250 0.92 1.4 1.4
Vaporizer VAP 350 1.6 2 1.9




















































Area Count/1000 150 250 400
VAP 250 2.5 2.2 1.2
Vaporizer VAP 350 2.9 2.8 1.2
VAP 450 3 2.5 1.1
10
Area Count/1000 150 250 400
VAP 250 0.043 0.088 0.11
Vaporizer VAP 350 0.087 0.12 0.084





















































Area Count/1000 150 250 400
VAP 250 0.13 0.14 0.03
Vaporizer VAP 350 0.23 0.18 0.043
VAP 450 0.19 0.19 0.044
12
Area Count/1000 150 250 400
VAP 250 1.4 1.5 0.3
Vaporizer VAP 350 2.2 1.6 0.3



















































Area Count/1000 150 250 400
VAP 250 0.015 0.014 0
Vaporizer VAP 350 0.045 0 0
VAP 450 0.11 0 0
14
Area Count/1000 150 250 400
VAP 250 0.19 0.51 0.06
Vaporizer VAP 350 0.66 0.62 0

























































Area Count/1000 150 250 400
VAP 250 0.74 0.6 0.15
Vaporizer VAP 350 0.81 0.46 0.11
VAP 450 0.86 0.4 0.09
16
Area Count/1000 150 250 400
VAP 250 0.16 0.16 0.026
Vaporizer VAP 350 0.24 0.1 0























































Area Count/1000 150 250 400
VAP 250 0.24 0.21 0.014
Vaporizer VAP 350 0.34 0.23 0.007
VAP 450 0.38 0.23 0
18
Area Count/1000 150 250 400
VAP 250 0.069 0.059 0.022
Vaporizer VAP 350 0.089 0.06 0.0087




























































Area Count/1000 150 250 400
VAP 250 0 0.058 0.049
Vaporizer VAP 350 0.005 0.17 0.024
VAP 450 0.007 0.45 0
20
Area Count/1000 150 250 400
VAP 250 0.82 0.6


























































Area Count/1000 150 250 400
VAP 250 1.48 0.73 0
Vaporizer VAP 350 1.68 0.57 0
VAP 450 1.61 0.25 0
22
Area Count/1000 150 250 400
VAP 250 1.2 1.5 0.084
Vaporizer VAP 350 1.3 1.1 0.05




























































Area Count/1000 150 250 400
VAP 250 0.21 0.17 0
Vaporizer VAP 350 0.42 0.097 0
VAP 450 0.47 0.016 0
24
Area Count/1000 150 250 400
VAP 250 0.4 0.43 0.11
Vaporizer VAP 350 0.54 0.35 0.12





















































Ion Tranfer Tube Temp.[C]
Vaporizer Temp. [C]
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Area Count/1000 150 250 400
VAP 250 0 0 0
Vaporizer VAP 350 0 0 0
VAP 450 0 0 0
Vaporizer - Heated Capillary Temperature Effect
31
Area Count/1000 150 250 400
VAP 250 1.5 1.11 0.021
Vaporizer VAP 350 1.5 0.87 0.0092




















































Area Count/1000 150 250 400
VAP 250 2.2 1.15 0.022
Vaporizer VAP 350 2.5 0.97 0.014
VAP 450 2 0.61 0
28
Area Count/1000 150 250 400
VAP 250 0 0.0029 0
Vaporizer VAP 350 0 0.0007 0




















































Area Count/1000 150 250 400
VAP 250 0.11 0.14 0
Vaporizer VAP 350 0.22 0.19 0
VAP 450 0.26 0.19 0
30
Area Count/1000 150 250 400
VAP 250 0 0 0
Vaporizer VAP 350 0 0 0
























































Area Count/1000 150 250 400
VAP 250 1.5 1.11 0.021
Vaporizer VAP 350 1.5 0.87 0.0092
VAP 450 1.3 0.5 0.008
32
Area Count/1000 150 250 400
VAP 250 0.066 0.04 0.022
Vaporizer VAP 350 0.07 0.055 0.019
VAP 450 0.079 0.045 0.021
Phostebupyrim Capillary


















































Area Count/1000 150 250 400
VAP 250 0.13 0.21 0
Vaporizer VAP 350 0.2 0.25 0
VAP 450 0.34 0.24 0
Vaporizer - Heated Capillary Temperature Effect
39
Area Count/1000 150 250 400
VAP 250 0.013 0.006 0
Vaporizer VAP 350 0.005 0.008 0























































Area Count/1000 150 250 400
VAP 250 0.7 1.2 0.17
Vaporizer VAP 350 1.4 1.1 0.12
VAP 450 1.6 0.77 0.099
36
Area Count/1000 150 250 400
VAP 250 0.012 0.04 0
Vaporizer VAP 350 0.086 0.077 0




























































Area Count/1000 150 250 400
VAP 250 0 0.023 0
Vaporizer VAP 350 0.013 0.011 0
VAP 450 0.036 0 0
38
Area Count/1000 150 250 400
VAP 250 0.13 0.21 0
Vaporizer VAP 350 0.2 0.25 0
























































Area Count/1000 150 250 400
VAP 250 0.013 0.006 0
Vaporizer VAP 350 0.005 0.008 0
VAP 450 0.014 0.0046 0
40
Area Count/1000 150 250 400
VAP 250 0.61 0.17 0
Vaporizer VAP 350 0.64 0 0























































Appendix 3B : Applied Solvent Gradient curves for testing HPLC columns and  
 
This section lists the solvent gradients and their reference codes used while developing 
the HPLC portion of the analytical separations.  
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Table 18   List of elution curves applied while optimizing LC separations 
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Table Table 18  (cont) List of elution curves applied while optimizing LC separations 
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Table Table 18  (cont) List of elution curves applied while optimizing LC separations 
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Table Table 18  (cont) List of elution curves applied while optimizing LC separations 
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Table Table 18  (cont) List of elution curves applied while optimizing LC separations 
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Table Table 18  (cont) List of elution curves applied while optimizing LC separations 
132 
 

























































































































Table Table 18  (cont) List of elution curves applied while optimizing LC separations 
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Table Table 18  (cont) List of elution curves applied while optimizing LC separations 
134 
Appendix 3C: ESI and APCI positive and negative full scan spectra 
050920ESIfs_01 #20 RT: 0.33 AV: 1 NL: 2.71E8
T: + c Q1MS [100.00-600.00]





















201.04143.01 294.51 389.98 477.56247.02 587.96351.03 491.51
 
050920ESI_Nfs_01 #22 RT: 0.37 AV: 1 NL: 3.34E7
T: - c Q1MS [100.00-1000.00]





















182.97136.93 386.82273.91 426.81295.84 591.74454.84 522.77
 
050922APCI_P_fs01 #7 RT: 0.11 AV: 1 NL: 2.50E8
T: + c Q1MS [100.00-1000.00]






















324.99168.04 389.97115.08 552.94522.93480.00 591.32
 
050922APCI_N_fs01 #6 RT: 0.09 AV: 1 NL: 5.12E7
T: - c Q1MS [100.00-1000.00]





















124.92 331.78279.86222.86 350.83 416.84 495.69 580.64550.69
 
Figure 64   Acephate ESI positive, ESI negative, APCI positive, APCI negative full scan spectra
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050920ESIfs_02 #30 RT: 0.51 AV: 1 NL: 1.94E8
T: + c Q1MS [100.00-600.00]




























050922APCI_P_fs02 #6-11 RT: 0.09-0.18 AV: 6 SB: 12 0.01-0.06 , 0.39-0.51 NL: 2.13E8
T: + c Q1MS [100.00-1000.00]





















318.97260.95132.03 451.04358.99289.97205.07 349.99 537.82469.04 599.7
050922APCI_N_fs02 #6-9 RT: 0.09-0.15 AV: 4 SB: 12 0.01-0.06 , 0.39-0.51 NL: 9.24E7
T: - c Q1MS [100.00-1000.00]




















224.83 301.84 338.73 481.72117.96 422.65 534.57 598.4273.84
Figure 65   Azinphos Methyl ESI positive, ESI negative, APCI positive, APCI negative full scan spectra 
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050920ESIfs_03 #49 RT: 0.83 AV: 1 NL: 2.85E8
T: + c Q1MS [100.00-600.00]




















420.03313.96 358.00184.04 218.03 497.18 581.03443.08151.08 254.90 533.02
050920ESI_Nfs_03 #22 RT: 0.37 AV: 1 SB: 23 0.06-0.25 , 0.46-0.63 NL: 5.31E6
T: - c Q1MS [100.00-1000.00]






















396.89 458.85 487.85214.96 311.01 398.93 578.79254.98 326.03196.91107.94
050922APCI_P_fs03 #7-12 RT: 0.11-0.20 AV: 6 NL: 2.53E8
T: + c Q1MS [100.00-1000.00]





















419.99313.90 596.9200.00115.07 441.05 554.96519.09222.07184.02
050922APCI_N_fs03 #7-12 RT: 0.11-0.20 AV: 6 SB: 12 0.01-0.06 , 0.39-0.51 NL: 1.35E8
T: - c Q1MS [100.00-1000.00]




















353.84140.89 537.86168.92 589.81293.80215.91 404.83 517.79443.74
Figure 66   Bensulide ESI positive, ESI negative, APCI positive, APCI negative full scan spectra 
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050920ESIfs_04 #27 RT: 0.46 AV: 1 NL: 2.81E8
T: + c Q1MS [100.00-600.00]





















563.13334.09312.10 564.12200.02 256.04 370.19 476.15 527.19172.00 422.22105.05
050920ESI_Nfs_04 #24 RT: 0.41 AV: 1 SB: 23 0.06-0.25 , 0.46-0.63 NL: 1.91E6
T: - c Q1MS [100.00-1000.00]





















395.91299.00 372.94136.92 442.91181.92 526.78 578.68
050922APCI_P_fs04 #11-14 RT: 0.18-0.23 AV: 4 NL: 3.11E8
T: + c Q1MS [100.00-1000.00]






















304.06 544.09247.01190.99 527.10471.01370.15162.97 442.95
050922APCI_N_fs04 #11-15 RT: 0.18-0.25 AV: 5 SB: 12 0.01-0.06 , 0.39-0.51 NL: 4.27E7
T: - c Q1MS [100.00-1000.00]




















258.87200.90 390.87140.88 376.76280.87 448.83 554.69510.70 596.7






























050922APCI_N_fs05 #17-22 RT: 0.29-0.37 AV: 6 SB: 12 0.01-0.06 , 0.39-0.51 NL: 1.55E7
T: - c Q1MS [100.00-1000.00]























197.83 310.69140.88 292.73 352.70 564.57414.68 482.64 538.54
























050922APCI_P_fs06 #22-28 RT: 0.37-0.48 AV: 7 NL: 2.28E8
T: + c Q1MS [100.00-1000.00]




















126.02 355.88162.01 217.03 315.94 405.88254.99 457.96 481.77 551.87 571.81
050922APCI_N_fs06 #21-29 RT: 0.36-0.50 AV: 9 NL: 2.23E7
T: - c Q1MS [100.00-1000.00]






















285.78 316.78215.81154.90 347.78245.78 380.76 490.71 533.63432.58 558.71




050920ESIfs_07 #29 RT: 0.49 AV: 1 NL: 8.51E6
T: + c Q1MS [100.00-600.00]






















370.20272.16 454.30 522.59240.15 541.20
050920ESI_Nfs_07 #26 RT: 0.44 AV: 1 SB: 23 0.06-0.25 , 0.46-0.63 NL: 2.42E6
T: - c Q1MS [100.00-1000.00]
























427.77 472.72355.02140.89 526.84 568.94
050922APCI_P_fs07 #14-16 RT: 0.23-0.27 AV: 3 SB: 8 0.15-0.20 , 0.32-0.37 NL: 2.78E7
T: + c Q1MS [100.00-1000.00]






















287.93196.01 271.07 327.91 377.91 427.91 452.89 486.76 534.07 580.06
050922APCI_N_fs07 #13-15 RT: 0.22-0.25 AV: 3 NL: 2.17E7
T: - c Q1MS [100.00-1000.00]
























142.88 317.76 361.68126.88 416.64 436.43 524.54 596.5
Figure 70   Chlorpyrifos Methyl ESI positive, ESI negative, APCI positive, APCI negative full scan spectra
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050920ESIfs_08 #27 RT: 0.46 AV: 1 NL: 7.40E7
T: + c Q1MS [100.00-600.00]




















404.02 426.03115.11 143.10 303.65271.08184.04 467.10329.08 522.56 550.60
050920ESI_Nfs_08 #20 RT: 0.34 AV: 1 SB: 23 0.06-0.25 , 0.46-0.64 NL: 2.15E6
T: - c Q1MS [100.00-1000.00]



















369.86332.81 415.87208.91137.95 254.86 304.86 472.48 579.57500.79
050922APCI_P_fs08 #9-14 RT: 0.15-0.23 AV: 6 SB: 8 0.15-0.20 , 0.32-0.37 NL: 1.12E8
T: + c Q1MS [100.00-1000.00]






















539.02218.05 427.98243.02 513.03301.04 572.97137.03
050922APCI_N_fs08 #7-12 RT: 0.11-0.20 AV: 6 NL: 5.09E7
T: - c Q1MS [100.00-1000.00]























318.80 400.78256.87 421.84 542.77335.82161.98 510.73 564.70
Figure 71   Coumaphos ESI positive, ESI negative (weak), APCI positive, APCI negative full scan spectra
142 
 
050920ESIfs_09 #49 RT: 0.83 AV: 1 NL: 3.19E8
T: + c Q1MS [100.00-600.00]





















327.07173.10 488.11359.15206.05 299.18 404.20 510.14457.12152.15 575.25
050920ESI_Nfs_09 #24 RT: 0.41 AV: 1 SB: 23 0.06-0.25 , 0.46-0.63 NL: 2.84E6
T: - c Q1MS [100.00-1000.00]





















299.00 345.02274.94181.92 372.99 416.99 461.08 504.97 570.67
050922APCI_P_fs09 #8-16 RT: 0.13-0.27 AV: 9 SB: 8 0.15-0.20 , 0.32-0.37 NL: 4.76E7
T: + c Q1MS [100.00-1000.00]




















319.08153.08 181.10 359.08291.06 457.14233.01 395.01 505.05 561.63
050922APCI_N_fs09 #8-11 RT: 0.13-0.18 AV: 4 NL: 5.78E7
T: - c Q1MS [100.00-1000.00]




















154.90 200.89 274.91236.88 346.84112.90 414.80 510.78482.79 564.75
Figure 72   Diazinon ESI positive, ESI negative, APCI positive, APCI negative full scan spectra 
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050920ESIfs_10 #24 RT: 0.40 AV: 1 NL: 1.11E8
T: + c Q1MS [100.00-600.00]





















265.98 444.90105.05 220.96 306.08182.09 525.05360.96 571.85407.23 464.88
050920ESI_Nfs_10 #19 RT: 0.32 AV: 1 SB: 23 0.06-0.25 , 0.46-0.63 NL: 7.89E6
T: - c Q1MS [100.00-1000.00]





















170.91 254.77 334.71 370.65208.81150.94 412.64 434.66 466.68 538.56 568.51
050922APCI_P_fs10 #7-10 RT: 0.11-0.16 AV: 4 SB: 4 0.02-0.08 NL: 1.15E8
T: + c Q1MS [100.00-1000.00]






















265.95 360.94233.01 332.94 446.86402.92 513.83 538.75 581.64
050922APCI_N_fs10 #5-6 RT: 0.08-0.09 AV: 2 NL: 6.61E7
T: - c Q1MS [100.00-1000.00]





















170.90124.91 254.79 434.63216.85 410.66302.76 352.76 502.67 582.61530.57
Figure 73   Dichlorvos ESI positive, ESI negative, APCI positive, APCI negative full scan spectra 
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050920ESIfs_11 #18 RT: 0.30 AV: 1 NL: 2.80E8
T: + c Q1MS [100.00-600.00]






















375.62271.10 498.13193.02 305.07 389.57130.08 533.11 583.11443.18
050920ESI_Nfs_11 #20 RT: 0.34 AV: 1 SB: 23 0.06-0.25 , 0.46-0.63 NL: 2.55E6
T: - c Q1MS [100.00-1000.00]




















468.85307.87 334.90213.88 267.81181.95 368.80 496.83 530.72427.83 574.73
050922APCI_P_fs11 #6-10 RT: 0.09-0.16 AV: 5 SB: 4 0.02-0.08 NL: 2.64E8
T: + c Q1MS [100.00-1000.00]






















238.06 349.11112.05 476.12144.08 364.05285.09 408.01193.01 555.98 579.0
050922APCI_N_fs11 #6-8 RT: 0.09-0.13 AV: 3 NL: 2.56E7
T: - c Q1MS [100.00-1000.00]























156.89 272.89 420.83216.91 340.85 384.74 568.76517.91452.60
Figure 74   Dicrotophos ESI positive, ESI negative, APCI positive, APCI negative full scan spectra 
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050920ESIfs_12 #21 RT: 0.35 AV: 1 NL: 2.16E8
T: + c Q1MS [100.00-600.00]





















198.98 592.57482.95305.08 363.46134.07 413.02 534.10
050920ESI_Nfs_12 #19 RT: 0.32 AV: 1 SB: 23 0.06-0.25 , 0.46-0.63 NL: 1.33E7
T: - c Q1MS [100.00-1000.00]




















317.89197.92134.92 252.87 502.76369.79 426.84 527.79485.90 581.75
050922APCI_P_fs12 #5-10 RT: 0.08-0.16 AV: 6 SB: 4 0.03-0.08 NL: 2.38E8
T: + c Q1MS [100.00-1000.00]























171.00 335.01115.06 386.01 437.99 544.10 595.5
050922APCI_N_fs12 #6-9 RT: 0.09-0.15 AV: 4 NL: 6.56E7
T: - c Q1MS [100.00-1000.00]




















158.86 385.78224.83140.87 369.79273.89 442.81 484.72 538.90 598.4
Figure 75   Dimethoate ESI positive, ESI negative, APCI positive, APCI negative full scan spectra 
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050920ESIfs_13 #27 RT: 0.46 AV: 1 NL: 5.57E7
T: + c Q1MS [100.00-600.00]





















230.00 270.12184.03 368.14312.30 444.04 525.20482.52 550.67
050920ESI_Nfs_13 #19 RT: 0.32 AV: 1 SB: 23 0.06-0.25 , 0.46-0.63 NL: 2.97E6
T: - c Q1MS [100.00-1000.00]




















213.91 273.85137.91 368.78 491.52345.07 432.73 577.11527.66
050922APCI_P_fs13 #10-18 RT: 0.16-0.30 AV: 9 SB: 4 0.03-0.08 NL: 2.67E8
T: + c Q1MS [100.00-1000.00]




















213.00 366.02275.01184.99106.06 487.01289.03217.00 458.97 522.90 584.73
050922APCI_N_fs13 #10-16 RT: 0.16-0.27 AV: 7 NL: 5.41E7
T: - c Q1MS [100.00-1000.00]




















154.87 252.84200.90 348.83320.79 378.76 430.78 452.76 512.63 540.77 580.83
Figure 76   Disulfoton ESI positive, ESI negative (weak), APCI positive, APCI negative full scan spectra
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050920ESIfs_14 #28 RT: 0.47 AV: 1 NL: 8.15E7
T: + c Q1MS [100.00-600.00]





























050922APCI_P_fs14 #21-28 RT: 0.36-0.48 AV: 8 SB: 4 0.02-0.08 NL: 3.18E8
T: + c Q1MS [100.00-1000.00]





















398.94185.02 232.98 338.95 438.94 491.00153.06 582.93281.03 556.86
050922APCI_N_fs14 #19-27 RT: 0.32-0.46 AV: 9 NL: 1.23E8
T: - c Q1MS [100.00-1000.00]




















354.78156.85 252.84 392.78334.78 430.79 562.71478.72 526.73
Figure 77   Ethion ESI positive, ESI negative, APCI positive, APCI negative full scan spectra 
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050920ESIfs_15 #21 RT: 0.35 AV: 1 NL: 2.75E8
T: + c Q1MS [100.00-600.00]





















244.04 508.07308.08 455.11115.07 213.06 547.15347.11173.11 425.14
050920ESI_Nfs_15 #16-26 RT: 0.27-0.44 AV: 11 SB: 18 0.02-0.15 , 0.56-0.72 NL: 4.70E5
T: - c Q1MS [100.00-1000.00]





















181.94 327.09 349.13 383.00 441.87 580.96523.09468.14
050922APCI_P_fs15 #7-13 RT: 0.11-0.22 AV: 7 SB: 4 0.02-0.08 NL: 3.04E8
T: + c Q1MS [100.00-1000.00]






















285.05 488.06455.08233.02 330.09146.05 425.11203.03 557.06 576.9
050922APCI_N_fs15 #6-12 RT: 0.09-0.20 AV: 7 NL: 8.08E7
T: - c Q1MS [100.00-1000.00]




















170.91124.92 376.82310.82 414.74 444.78 510.79 554.73 582.78
Figure 78   Ethoprop ESI positive, ESI negative (weak), APCI positive, APCI negative full scan spectra
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050920ESIfs_16 #26 RT: 0.44 AV: 1 NL: 1.74E7
T: + c Q1MS [100.00-600.00]
























270.11 323.07 359.19230.04 386.00 485.14454.29 554.03 569.41
050920ESI_Nfs_16 #22 RT: 0.37 AV: 1 SB: 11 0.01-0.18 NL: 4.03E5
T: - c Q1MS [100.00-1000.00]























237.68 301.01 441.83181.92 461.12 540.49 581.22
050922APCI_P_fs16 #8-14 RT: 0.13-0.23 AV: 7 SB: 4 0.03-0.08 NL: 1.75E8
T: + c Q1MS [100.00-1000.00]






















230.04152.06 324.00 432.05371.09 584.03523.09493.97
050922APCI_N_fs16 #6-12 RT: 0.09-0.20 AV: 7 NL: 4.08E7
T: - c Q1MS [100.00-1000.00]






















546.77245.87 400.84 524.82453.80330.82 575.84











050920ESI_Nfs_17 #18 RT: 0.30 AV: 1 SB: 11 0.01-0.18 NL: 5.76E5
T: - c Q1MS [100.00-1000.00]






















306.99 369.73147.97 415.01 548.78456.84 586.02487.15
050922APCI_P_fs17 #7-14 RT: 0.11-0.23 AV: 8 SB: 4 0.03-0.08 NL: 2.68E8
T: + c Q1MS [100.00-1000.00]






















512.20250.13209.12 548.08101.10 485.16409.11 596.0146.07
050922APCI_N_fs17 #6-11 RT: 0.09-0.18 AV: 6 SB: 6 0.03-0.04 , 0.27-0.32 NL: 4.30E6
T: - c Q1MS [100.00-1000.00]





















136.93 382.82156.89 232.89 319.91 516.84409.91 584.80494.80




050920ESIfs_18 #22 RT: 0.37 AV: 1 SB: 24 0.06-0.23 , 0.63-0.83 NL: 1.11E7
T: + c Q1MS [100.00-600.00]





















367.12304.11261.08146.07 211.15 345.16274.37 368.14 454.29 488.37 522.43 567.01
050920ESI_Nfs_17 #16-20 RT: 0.27-0.34 AV: 5 SB: 11 0.01-0.18 NL: 4.37E5
T: - c Q1MS [100.00-1000.00]






















393.90306.92147.90 414.88 504.97 586.15565.33
050922APCI_P_fs18 #7-11 RT: 0.11-0.18 AV: 5 SB: 4 0.02-0.08 NL: 1.22E8
T: + c Q1MS [100.00-1000.00]























262.02179.07 294.04216.06 371.09 401.04 495.07 525.02431.07 555.19
050922APCI_N_fs18 #7-15 RT: 0.11-0.25 AV: 9 SB: 6 0.02-0.04 , 0.27-0.32 NL: 3.99E7
T: - c Q1MS [100.00-1000.00]






















276.85208.86 305.93135.95 414.86344.86 546.81493.70436.86 586.73
Figure 81   Fenitrothion ESI positive (weak),, ESI negative, APCI positive, APCI negative full scan spectra
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050920ESIfs_19 #26 RT: 0.44 AV: 1 SB: 24 0.06-0.23 , 0.63-0.83 NL: 1.88E7
T: + c Q1MS [100.00-600.00]























343.04173.09 512.16261.50 378.14 451.05208.05
050920ESI_Nfs_19 #23-29 RT: 0.39-0.50 AV: 7 SB: 11 0.01-0.18 NL: 3.80E6
T: - c Q1MS [100.00-1000.00]




















299.04 382.87345.06107.91 213.84181.93 523.17417.03 555.03460.81
050922APCI_P_fs19 #8-14 RT: 0.13-0.23 AV: 7 SB: 4 0.02-0.08 NL: 7.07E7
T: + c Q1MS [100.00-1000.00]






















106.05 325.00154.04 385.01 557.01233.15 429.08 491.07 579.0
050922APCI_N_fs19 #7-15 RT: 0.11-0.25 AV: 9 SB: 6 0.02-0.04 , 0.27-0.32 NL: 8.55E6
T: - c Q1MS [100.00-1000.00]



















263.86186.89140.91 330.84308.83208.86 398.82 548.76 596.6466.85 520.56
Figure 82   Fenthion ESI positive, ESI negative, APCI positive, APCI negative full scan spectra
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050920ESIfs_20 #23 RT: 0.39 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 1.20E7
T: + c Q1MS [100.00-600.00]























368.16245.54 312.29248.05 524.01454.28369.17 538.71
050920ESI_Nfs_20 #20-23 RT: 0.34-0.39 AV: 4 SB: 11 0.01-0.18 NL: 7.29E5
T: - c Q1MS [100.00-1000.00]






















050922APCI_P_fs20 #8-17 RT: 0.13-0.29 AV: 10 SB: 4 0.03-0.08 NL: 2.90E8
T: + c Q1MS [100.00-1000.00]




















261.02169.03 215.04106.06 353.05310.11 383.10 459.09 503.12 547.25 595.0
050922APCI_N_fs20 #9-15 RT: 0.15-0.25 AV: 7 NL: 1.39E7
T: - c Q1MS [100.00-1000.00]




















184.92 216.87 284.85 304.84 352.78 408.83 446.68 484.96 514.63 572.91
Figure 83   Fonofos ESI positive, ESI negative, APCI positive, APCI negative full scan spectra
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050920ESIfs_21 #19 RT: 0.32 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 2.00E8
T: + c Q1MS [100.00-600.00]




















285.00 348.05 394.04115.10 430.13257.03 515.11159.06 217.13 488.08 558.19 586.0
050920ESI_Nfs_21 #20-25 RT: 0.34-0.43 AV: 6 SB: 11 0.01-0.18 NL: 6.64E6
T: - c Q1MS [100.00-1000.00]



















315.86156.87 360.85233.04 299.00 317.86213.83 416.99 437.48 543.68494.83 568.88
050922APCI_P_fs21 #7-13 RT: 0.11-0.22 AV: 7 SB: 4 0.03-0.08 NL: 2.39E8
T: + c Q1MS [100.00-1000.00]





















352.99247.03173.06115.06 394.02 550.86437.06 486.96 587.03
050922APCI_N_fs21 #9 RT: 0.15 AV: 1 SB: 11 0.03-0.09 , 0.27-0.36 NL: 6.47E7
T: - c Q1MS [100.00-1000.00]



















314.87158.87 224.84 336.71142.88 292.80 424.60 494.79159.86 536.57 598.5
Figure 84   Malathion ESI positive, ESI negative, APCI positive, APCI negative full scan spectra 
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050920ESIfs_22 #23 RT: 0.39 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 2.72E8
T: + c Q1MS [100.00-600.00]




















183.04 285.02205.01 372.50267.07 443.03126.05 479.34 549.30 587.66
050920ESI_Nfs_22 #22 RT: 0.37 AV: 1 SB: 11 0.01-0.18 NL: 5.07E6
T: - c Q1MS [100.00-1000.00]




















110.88 263.83156.92 278.83188.93 369.82 385.66 486.51 530.38 580.79461.24
050922APCI_P_fs22 #6-10 RT: 0.09-0.16 AV: 5 SB: 4 0.03-0.08 NL: 2.52E8
T: + c Q1MS [100.00-1000.00]


































050920ESIfs_23 #26 RT: 0.44 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 6.84E7
T: + c Q1MS [100.00-600.00]



















365.98304.94115.10 473.00145.01 367.99324.94183.04 474.88218.08 402.07252.99 548.07 595.2
050920ESI_Nfs_23 #20-27 RT: 0.34-0.46 AV: 8 SB: 11 0.01-0.18 NL: 9.39E5
T: - c Q1MS [100.00-1000.00]




















417.89 460.93374.03 504.94 548.87 581.09
050922APCI_P_fs23 #7-10 RT: 0.11-0.16 AV: 4 SB: 4 0.02-0.08 NL: 2.18E8
T: + c Q1MS [100.00-1000.00]



















304.94177.03 365.93115.07 319.96218.04 522.82446.92366.92286.99 586.69
050922APCI_N_fs23 #6-11 RT: 0.09-0.18 AV: 6 SB: 4 0.01-0.06 NL: 6.80E7
T: - c Q1MS [100.00-1000.00]




















224.83 466.71142.86 422.66 534.60354.76 598.5242.77
Figure 86   Methidathion ESI positive, ESI negative, APCI positive, APCI negative full scan spectra 
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050920ESIfs_24 #27 RT: 0.46 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 1.38E7
T: + c Q1MS [100.00-600.00]




















198.05 254.09 312.28 368.17 394.11 455.45 495.08 528.41 580.18
050920ESI_Nfs_24 #19-29 RT: 0.32-0.50 AV: 11 SB: 11 0.01-0.18 NL: 3.72E6
T: - c Q1MS [100.00-1000.00]























138.95 464.00387.88 479.07 595.1553.70
050922APCI_P_fs24 #5-9 RT: 0.08-0.15 AV: 5 NL: 1.56E8
T: + c Q1MS [100.00-1000.00]























152.08 192.12 316.06243.06 343.06 391.25 467.02 497.03 536.00 564.14
050922APCI_N_fs24 #6-11 RT: 0.09-0.18 AV: 6 SB: 4 0.01-0.06 NL: 3.65E7
T: - c Q1MS [100.00-1000.00]
























386.82315.82205.90 401.81 518.73463.79 586.69




050920ESIfs_25 #24 RT: 0.40 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 1.56E8
T: + c Q1MS [100.00-600.00]





















168.05 472.03 580.11289.03 356.09 505.03127.02 427.13
050920ESI_Nfs_25 #20-26 RT: 0.34-0.44 AV: 7 SB: 10 0.06-0.22 NL: 6.36E5
T: - c Q1MS [100.00-1000.00]























296.92 334.88 368.78 468.89420.71 530.72 558.79
050922APCI_P_fs25 #7-13 RT: 0.11-0.22 AV: 7 NL: 2.57E8
T: + c Q1MS [100.00-1000.00]






















289.05 352.01 471.02106.05 394.98 528.99 590.98
050922APCI_N_fs25 #6-9 RT: 0.10-0.15 AV: 4 SB: 4 0.01-0.06 NL: 3.63E7
T: - c Q1MS [100.00-1000.00]





















156.91 250.88208.91 272.86 420.80384.80356.82 568.77504.83438.64
Figure 88   Mevinphos ESI positive, ESI negative, APCI positive, APCI negative full scan spectra 
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050920ESIfs_26 #25 RT: 0.42 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 2.11E7
T: + c Q1MS [100.00-600.00]





















419.79257.08168.06 412.82 453.82146.07 380.75 491.01252.12183.06 334.25 508.82 592.69
050920ESI_Nfs_26 #20-27 RT: 0.34-0.46 AV: 8 SB: 10 0.06-0.22 NL: 1.33E7
T: - c Q1MS [100.00-1000.00]






















408.60 414.57 578.3254.73 458.56170.91 370.60218.86124.91 570.42334.72271.72 490.54
050922APCI_P_fs26 #6-10 RT: 0.09-0.16 AV: 5 NL: 2.82E7
T: + c Q1MS [100.00-1000.00]

























298.94141.05 235.01 391.21 506.76346.96 547.68 598.6
050922APCI_N_fs26 #6-8 RT: 0.09-0.13 AV: 3 SB: 4 0.01-0.06 NL: 1.90E7
T: - c Q1MS [100.00-1000.00]





















204.81 362.59172.82 250.75 368.58
206.80
218.81 410.59252.76 286.64 468.49 572.39538.49159.74
Figure 89   Naled ESI positive, ESI negative, APCI positive, APCI negative full scan spectra 
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050920ESIfs_27 #20 RT: 0.33 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 2.49E8
T: + c Q1MS [100.00-600.00]





















169.02 389.02 530.99115.07 310.03229.05 339.10 417.72 484.09 586.56
050920ESI_Nfs_27 #18-24 RT: 0.30-0.41 AV: 7 SB: 10 0.06-0.22 NL: 6.57E5
T: - c Q1MS [100.00-1000.00]

























364.80 400.75 520.78455.45 597.1
050922APCI_P_fs27 #5-14 RT: 0.08-0.23 AV: 10 NL: 2.18E8
T: + c Q1MS [100.00-1000.00]





















168.99 492.98 514.97268.98210.02139.01 310.02 338.95 416.95 446.93 545.14
050922APCI_N_fs27 #5-8 RT: 0.08-0.13 AV: 4 SB: 4 0.01-0.06 NL: 3.47E7
T: - c Q1MS [100.00-1000.00]




















230.86 304.78170.92124.91 282.81208.85 394.77306.80 468.73 490.67 558.67 578.6




050920ESIfs_28 #29 RT: 0.49 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 9.46E6
T: + c Q1MS [100.00-600.00]





















339.02173.08 310.13269.01247.01 423.23 510.93462.28 582.12
050920ESI_Nfs_28 #18-23 RT: 0.30-0.39 AV: 6 SB: 10 0.06-0.22 NL: 8.83E5
T: - c Q1MS [100.00-1000.00]























250.02214.91 432.72384.68 461.00 583.19556.58
050922APCI_P_fs28 #10-17 RT: 0.16-0.29 AV: 8 NL: 1.77E8
T: + c Q1MS [100.00-1000.00]





















262.98244.97 340.97198.98106.05 159.02 508.89277.03 413.00 444.98 572.86
050922APCI_N_fs28 #9-17 RT: 0.15-0.29 AV: 9 SB: 4 0.01-0.06 NL: 6.62E7
T: - c Q1MS [100.00-1000.00]



















186.88170.88 230.86140.88 392.78 478.71348.77320.78 438.77 542.64 588.63
Figure 91   Phorate ESI positive, ESI negative (weak), APCI positive, APCI negative full scan spectra 
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050920ESIfs_29 #27 RT: 0.46 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 6.99E6
T: + c Q1MS [100.00-600.00]





















571.61389.99265.06 334.10 433.96183.07 467.10 562.51208.05
050920ESI_Nfs_29 #18-25 RT: 0.30-0.43 AV: 8 SB: 10 0.04-0.20 NL: 1.10E6
T: - c Q1MS [100.00-1000.00]




















321.81 411.78337.79134.94 184.91 215.87 413.78 457.82339.82257.88 490.70 534.71 580.18
050922APCI_P_fs29 #10-16 RT: 0.16-0.27 AV: 7 NL: 1.31E8
T: + c Q1MS [100.00-1000.00]





















188.03 477.01142.07 389.95 510.98190.04 421.97246.01 260.99 334.01 554.98 580.03
050922APCI_N_fs29 #9-16 RT: 0.15-0.27 AV: 8 SB: 4 0.01-0.06 NL: 1.25E8
T: - c Q1MS [100.00-1000.00]



















167.89 186.88 337.77252.84 392.79303.83156.88 551.78531.68478.73430.74 587.59
Figure 92   Phosalone ESI positive (weak), ESI negative, APCI positive, APCI negative full scan spectra
163 
 
050920ESIfs_30 #24 RT: 0.40 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 1.89E7
T: + c Q1MS [100.00-600.00]





















495.55381.99319.00143.13 260.48192.07 529.15448.06417.06 562.83
050920ESI_Nfs_30 #19-27 RT: 0.32-0.46 AV: 9 SB: 10 0.04-0.20 NL: 2.21E6
T: - c Q1MS [100.00-1000.00]





















302.83 347.78200.92 413.82 435.62268.86 534.53481.42 593.69
050922APCI_P_fs30 #6-10 RT: 0.09-0.16 AV: 5 NL: 1.83E8
T: + c Q1MS [100.00-1000.00]




















318.96 477.99115.07 224.06192.05 380.97166.07 537.83451.02 479.99301.99233.09 583.00
050922APCI_N_fs30 #5-10 RT: 0.08-0.16 AV: 6 SB: 4 0.01-0.06 NL: 8.79E7
T: - c Q1MS [100.00-1000.00]



















158.86 336.74224.82 301.81 481.73422.66 536.58142.85 352.71 598.5
Figure 93   Phosmet ESI positive, ESI negative (weak), APCI positive, APCI negative full scan spectra
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050920ESIfs_31 #31 RT: 0.52 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 2.10E8
T: + c Q1MS [100.00-600.00]




















321.11 360.13173.07 277.08105.03 247.01 502.16454.28 543.19 595.1432.10
050920ESI_Nfs_31 #23-28 RT: 0.39-0.48 AV: 6 SB: 10 0.04-0.20 NL: 8.72E5
T: - c Q1MS [100.00-1000.00]





















250.00 299.08 345.03233.04154.93 580.93426.76 506.95372.96327.08213.89 460.91 569.17
050922APCI_P_fs31 #14-28 RT: 0.23-0.48 AV: 15 NL: 2.94E8
T: + c Q1MS [100.00-1000.00]






















334.10154.08 385.03106.04 241.09 597.0471.23 515.32 568.97427.27
050922APCI_N_fs31 #14-23 RT: 0.23-0.39 AV: 10 SB: 4 0.01-0.06 NL: 1.04E8
T: - c Q1MS [100.00-1000.00]




















572.91550.93182.92 276.92 342.89196.99151.00 574.92426.97 480.89398.87
Figure 94   Phostebupirim ESI positive, ESI negative, APCI positive, APCI negative full scan spectra 
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050920ESIfs_32 #29 RT: 0.49 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 2.38E8
T: + c Q1MS [100.00-600.00]





















309.06173.08105.04 347.12196.11 552.10266.12 489.11404.61 454.29 576.04
050920ESI_Nfs_32 #21-26 RT: 0.36-0.44 AV: 6 SB: 10 0.04-0.20 NL: 3.77E6
T: - c Q1MS [100.00-1000.00]



















136.92 290.92 335.92250.01 434.76373.02181.91 581.09460.90 518.88
050922APCI_P_fs32 #8-19 RT: 0.13-0.32 AV: 12 NL: 3.13E8
T: + c Q1MS [100.00-1000.00]





















320.06183.11153.09 360.06277.06 487.19 509.17416.04 562.16
050922APCI_N_fs32 #9-13 RT: 0.15-0.22 AV: 5 SB: 4 0.01-0.06 NL: 1.09E7
T: - c Q1MS [100.00-1000.00]





















290.93208.84142.90 357.91276.78124.91 434.71412.79 453.77 531.14 587.96
Figure 95   Pirimphos methyl ESI positive, ESI negative, APCI positive, APCI negative (weak)       full 
scan spectra  
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050920ESIfs_33 #24 RT: 0.40 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 1.61E8
T: + c Q1MS [100.00-600.00]




















415.96374.93 437.93115.09 309.08 478.93224.13 515.91183.08 254.11 556.98
050920ESI_Nfs_33 #22-30 RT: 0.37-0.51 AV: 9 SB: 11 0.03-0.20 NL: 3.11E6
T: - c Q1MS [100.00-1000.00]























198.93 252.78152.94 390.72298.96 412.72 520.58496.83 548.59 581.0
050922APCI_P_fs33 #13-21 RT: 0.22-0.36 AV: 9 NL: 1.99E8
T: + c Q1MS [100.00-1000.00]























415.92319.07182.11 295.00153.08 254.99 447.96 509.92 528.89 572.94
 
050922APCI_N_fs33 #12-21 RT: 0.20-0.36 AV: 10 SB: 4 0.01-0.06 NL: 5.79E6
T: - c Q1MS [100.00-1000.00]























372.75170.90 398.69 432.60 470.60 514.64 550.62
Figure 96   Profenofos ESI positive, ESI negative, APCI positive, APCI negative full scan spectra
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050920ESIfs_34 #23-27 RT: 0.39-0.46 AV: 5 NL: 7.97E7
T: + c Q1MS [100.00-600.00]





















197.05156.03 240.04 394.14 416.09 564.17345.09 457.18115.10 516.79
050920ESI_Nfs_34 #19-25 RT: 0.32-0.43 AV: 7 SB: 11 0.03-0.20 NL: 1.51E6
T: - c Q1MS [100.00-1000.00]























250.01213.86 438.99393.97 483.97 579.98134.92 534.00
050922APCI_P_fs34 #7-13 RT: 0.11-0.22 AV: 7 SB: 3 0.02-0.06 NL: 1.70E8
T: + c Q1MS [100.00-1000.00]





















198.05170.00 329.10 391.05144.08 419.06 535.10 563.12479.11
050922APCI_N_fs34 #6-11 RT: 0.09-0.18 AV: 6 SB: 4 0.01-0.06 NL: 6.58E7
T: - c Q1MS [100.00-1000.00]






















221.87155.92 347.89 392.87 434.90140.89 283.90265.92 511.80481.72 560.89
Figure 97   Propetamphos ESI positive, ESI negative, APCI positive, APCI negative full scan spectra 
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050920ESIfs_35 #21-26 RT: 0.35-0.44 AV: 6 NL: 9.31E7
T: + c Q1MS [100.00-600.00]




















324.00115.10 282.08173.08 386.02 447.00 503.09263.08 570.97
050920ESI_Nfs_35 #18-25 RT: 0.30-0.43 AV: 8 SB: 10 0.04-0.20 NL: 1.09E6
T: - c Q1MS [100.00-1000.00]
























250.02107.92 364.72184.90 418.82327.08 540.70 581.15461.25
050922APCI_P_fs35 #7-17 RT: 0.11-0.29 AV: 11 SB: 3 0.03-0.06 NL: 2.86E8
T: + c Q1MS [100.00-1000.00]





















115.07 321.99 386.00217.05185.03 240.07 468.95 522.97 554.93
050922APCI_N_fs35 #9-12 RT: 0.15-0.20 AV: 4 SB: 4 0.01-0.06 NL: 1.39E7
T: - c Q1MS [100.00-1000.00]























294.84 332.83222.86126.87 470.80 510.76400.83 538.85 592.46
Figure 98   Sulfotepp ESI positive, ESI negative, APCI positive, APCI negative full scan spectra 
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050920ESIfs_36 #24 RT: 0.40 AV: 1 SB: 21 0.11-0.30 , 0.54-0.68 NL: 1.27E7
T: + c Q1MS [100.00-600.00]






















263.09 340.07173.09 386.07 499.02242.48 484.00263.92 531.92 589.27
050920ESI_Nfs_36 #18-23 RT: 0.30-0.39 AV: 6 SB: 11 0.03-0.20 NL: 3.37E6
T: - c Q1MS [100.00-1000.00]




















497.84453.76178.95 340.86200.93 562.83386.80273.84 430.74
050922APCI_P_fs36 #19-31 RT: 0.32-0.53 AV: 13 SB: 3 0.02-0.06 NL: 3.21E8
T: + c Q1MS [100.00-1000.00]





















499.97436.96218.01173.06 556.91319.09 356.03 592.9389.03143.03 251.12
050922APCI_N_fs36 #21-26 RT: 0.36-0.44 AV: 6 SB: 4 0.01-0.06 NL: 2.55E7
T: - c Q1MS [100.00-1000.00]






















356.83262.90 518.79208.84 453.81142.87 276.82 586.70124.92 424.79
Figure 99   Temephos ESI positive (weak), ESI negative, APCI positive, APCI negative full scan spectra
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050920ESIfs_37 #30 RT: 0.51 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 2.63E7
T: + c Q1MS [100.00-600.00]





















115.08 289.04 320.13173.09 244.97 393.08321.10143.12 466.98277.09 569.03208.05 539.01
050920ESI_Nfs_37 #22-29 RT: 0.37-0.50 AV: 8 SB: 10 0.04-0.20 NL: 1.81E6
T: - c Q1MS [100.00-1000.00]




















149.88 450.81 491.61349.06 581.23214.88 393.76 529.13
050922APCI_P_fs37 #16-21 RT: 0.27-0.36 AV: 6 SB: 3 0.02-0.06 NL: 2.50E8
T: + c Q1MS [100.00-1000.00]























103.03 536.91198.98 248.95 337.00 466.96439.03 598.9
050922APCI_N_fs37 #16-23 RT: 0.27-0.39 AV: 8 SB: 4 0.01-0.06 NL: 5.71E7
T: - c Q1MS [100.00-1000.00]




















252.85 392.82364.78 480.69140.92 450.75334.81 558.67 588.7512.72
Figure 100   Terbufos ESI positive (weak), ESI negative, APCI positive, APCI negative full scan spectra
171 
 
050920ESIfs_38 #27 RT: 0.46 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 3.50E7
T: + c Q1MS [100.00-600.00]
























431.89319.11105.04 466.00141.14 589.49505.95230.20 288.29
050920ESI_Nfs_38 #20-27 RT: 0.34-0.46 AV: 8 SB: 10 0.04-0.20 NL: 1.50E6
T: - c Q1MS [100.00-1000.00]























418.04 505.06250.00173.91 549.04298.93 434.78 593.05484.96
050922APCI_P_fs38 #8-13 RT: 0.13-0.22 AV: 6 SB: 3 0.02-0.06 NL: 2.33E8
T: + c Q1MS [100.00-1000.00]






















115.06 411.88173.04 506.89322.99 465.96271.04244.05 536.82 563.78
050922APCI_N_fs38 #6-11 RT: 0.09-0.18 AV: 6 SB: 4 0.01-0.06 NL: 4.25E7
T: - c Q1MS [100.00-1000.00]





















192.88 216.90156.94 354.70 396.68260.83 328.77 564.87498.65441.03
Figure 101   Tetrachlorvinphos ESI positive, ESI negative, APCI positive, APCI negative full scan spectra
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050920ESIfs_39 #35 RT: 0.59 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 6.52E7
T: + c Q1MS [100.00-600.00]





























050922APCI_P_fs39 #35-46 RT: 0.60-0.79 AV: 12 SB: 3 0.02-0.06 NL: 2.89E8
T: + c Q1MS [100.00-1000.00]






















050922APCI_N_fs39 #32-45 RT: 0.55-0.77 AV: 14 SB: 4 0.01-0.06 NL: 1.80E8
T: - c Q1MS [100.00-1000.00]




















324.86270.93 392.83 420.80140.88 186.89 488.78 536.81 568.85
Figure 102   Tribufos ESI positive, ESI negative, APCI positive, APCI negative full scan spectra 
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050920ESIfs_40 #19 RT: 0.32 AV: 1 SB: 26 0.06-0.23 , 0.59-0.83 NL: 7.20E7
T: + c Q1MS [100.00-600.00]























518.83105.03 152.07 323.93 368.96 534.82221.00 480.91439.89 556.70
050920ESI_Nfs_40 #17-22 RT: 0.29-0.37 AV: 6 SB: 25 0.08-0.29 , 0.60-0.79 NL: 6.45E6
T: - c Q1MS [100.00-1000.00]





















134.93 319.75 350.78204.83 240.77 558.64512.66428.74 460.63 580.6
050922APCI_P_fs40 #5-9 RT: 0.08-0.15 AV: 5 SB: 8 0.01-0.04 , 0.39-0.46 NL: 1.04E8
T: + c Q1MS [100.00-1000.00]





















221.02 288.93115.06 166.05 368.91301.94
514.82382.93 437.88 550.84 572.98
050922APCI_N_fs40 #6-8 RT: 0.09-0.13 AV: 3 SB: 6 0.02-0.06 , 0.22-0.25 NL: 1.19E7
T: - c Q1MS [100.00-1000.00]























354.75250.81 498.61388.69 462.63 526.61 570.58
Figure 103   Trichlorfon ESI positive, ESI negative, APCI positive, APCI negative full scan spectra
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CHAPTER 4:  SAMPLE CLEANUP AND METHOD APPLICATION 
When analyzing biological samples, almost always the first step is cleanup, followed 
by sample concentration. The preferred first step is solid phase extraction (SPE) because 
it is relatively inexpensive, easy to automatise, and a quick method. 
It was clear from previous [35] work, that SPE unlikely to be successful because the 
analytes of interests encompass a very wide range of physical properties. Particularly the 
highly hydrophilic analytes, like acephate and methamidophos are very difficult to retain 
together with hydrophobic OP pesticides.  
Also based on experiences in [35] the better cleanup method is lyophilization or freeze 
drying. When working with urine as matrix, freeze drying yielded very good result. It is 
not as easy to automatise as SPE, but the actual manual preparation is limited, and small 
amounts of solvent can remove most of the analytes. Reasons against lyophilization are 
that it requires specialized equipment, and it is a long process, creating a bottleneck in the 
cleanup procedure. 
Should lyophilization fail, there are number of options, essentially variants of liquid-
liquid extraction (LLE): 
• Manual liquid-liquid extraction. It can yield good information on feasibility for 
a certain solvent, but uses a lot of it and practically impossible to automatise. 
• Cartridge based LLE, such as Varian’s ChemElut. It is a form of LLE, but 
because the hydrophilic carrier increases surface area, it can have good results 
with less solvent. 
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• Accelerated solvent extraction (ASE) is a LLE carried out under pressure and 
potentially elevated temperatures. While it uses more solvent than the 
ChemElut system does, it is an automated process 
 
Liquid-Liquid Extraction on Solid Backing 
Since ChemElut cartridges perform similarly to LLE in a flask, it is a good starting 
point for investigating LLE feasibility. ChemElut cartridges are made by Varian, Inc., 
and they serve as an alternative to the conventional liquid-liquid extraction. These 
cartridges are ultrapure polypropylene tubes filled with Hydromatrix. Hydromatrix is a 
purified and of controlled particle size diatomaceous earth.  
When performing liquid-liquid extraction with a ChemElut cartridge, the aqueous 
sample first added to the tube. The Hydromatrix adsorbs the water on the surface of the 
particles and generates a very large potential contact surface wit the extraction solvent. 
After an approximately 3-5 minutes waiting, the eluent is added and led gravity-flow 
through the system. The stationary Hydromatrix does not let the aqueous sample to 
escape from the cartridge. The organic solvent surrounds the immobilized sample and the 
extraction process takes place. ChemElut cartridges are a good alternative to manual 
liquid/liquid extraction. In the experiments testing the ChemElut cartridges, 1ml serum 
samples were used spiked with 500 ng/mL OP pesticides. Recoveries were calculated 
according to the method described in Appendix 4B.  
The results of the experiments are summarized in Table 20 and Table 21. First (Table 
20), serum samples were tested on 3mL ChemElut cartridges with ethyl ether, ethyl 
acetate, dichloromethane, 1-chlorobutane, toluene and hexane as extraction solvent 
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candidates. In the second round of experiments (Table 21), ethyl acetate, 
dichloromethane and hexane were tested by themselves and in combination. In the first 
screening 5 mL solvent was used. In the second group the amount of solvent was 
increased to 2 x 5mL. From the tested neat and combination solvents, ethyl acetate was 









MMP 2.3% 17.8% 4.2% 1.0% 0.9% 0.1%
Acephate 0.7% 8.7% 1.8% 0.1% 0.1% 0.0%
Oxydemethon Methyl 3.6% 9.9% 2.9% 1.0% 0.9% 0.6%
Dimethoate 3.5% 9.5% 2.3% 1.3% 0.8% 0.3%
Trichlorfon 4.3% 13.9% 4.2% 3.7% 10.0% 2.7%
Dichlorvos 8.7% 2.4% 3.1% 5.3% 3.1% 0.2%
Methidathion 28.6% 12.4% 20.2% 10.9% 8.7% 8.5%
Propetamphos 0.0% 0.0% 33.2% 14.3% 19.0% 9.1%
Ethoprop 27.3% 23.4% 17.2% 8.4% 9.6% 3.8%
Azinphos Me 0.0% 0.0% 28.7% 16.8% 14.1% 41.3%
Pirimphos Me 0.1% 14.6% 9.0% 7.3% 6.8% 13.5%
Tetrachlorvinphos 11.7% 21.9% 0.0% 6.0% 7.1% 5.8%
Fonofos 0.0% 0.0% 12.4% 7.7% 8.2% 6.2%
Bensulide 0.0% 0.0% 0.0% 25.1% 26.8% 4.1%
Coumaphos 0.0% 6.4% 0.0% 37.4% 33.9% 15.3%
Chlorpyrifos 0.0% 0.0% 3.5% 8.0% 7.6% 0.4%
Ethion 0.0% 0.0% 0.0% 39.0% 12.1% 11.6%
Tribufos 22.4% 26.8% 0.0% 33.0% 34.4% 29.8%
Temephos 0.0% 14.0% 0.0% 36.2% 31.4% 46.0%










MMP 16.3% 42.7% 35.7% 0.6% 0.6% 0.2% 
Acephate 3.5% 23.8% 17.3% 0.0% 0.0% 0.0% 
Oxydemethon Methyl 4.3% 33.3% 87.5% 0.2% 1.1% 0.3% 
Dimethoate 81.2% 84.8% 87.7% 74.6% 78.4% 0.1% 
Trichlorfon 80.9% 38.8% 40.4% 71.3% 93.9% 3.8% 
Dichlorvos 75.4% 16.2% 9.0% 10.3% 25.3% 3.6% 
Methidathion 23.7% 23.6% 19.1% 25.7% 27.6% 27.8% 
Propetamphos 12.7% 13.1% 10.9% 16.7% 14.2% 18.5% 
Ethoprop 38.0% 30.6% 22.4% 30.9% 37.6% 26.6% 
Azinphos Me 22.8% 18.0% 16.8% 16.6% 17.1% 11.5% 
Pirimphos Me 13.0% 13.5% 10.0% 14.9% 15.9% 21.5% 
Tetrachlorvinphos 16.7% 14.5% 16.6% 18.8% 19.8% 10.3% 
Fonofos 14.3% 11.1% 12.9% 20.5% 20.3% 26.9% 
Bensulide 11.8% 10.9% 11.5% 20.1% 21.6% 0.0% 
Coumaphos 13.3% 12.0% 5.8% 16.2% 14.2% 16.4% 
Chlorpyrifos 8.8% 9.4% 4.8% 10.5% 8.7% 19.2% 
Ethion 8.0% 8.6% 3.1% 6.5% 6.3% 18.2% 
Tribufos 9.4% 10.5% 4.8% 10.7% 9.5% 17.2% 
Temephos 0.5% 5.9% 1.5% 2.4% 2.2% 10.6% 





Ethyl Acetate Dichloro 
methane 













MMP 45.7% 24.2% 0.3% 12.4% 38.3% 20.7% 0.2% 
Acephate 44.3% 36.1% 0.2% 19.7% 45.4% 19.6% 0.1% 
Oxydemethon Methyl 43.5% 71.8% 0.5% 45.6% 60.6% 26.0% 0.1% 
Dimethoate 75.6% 74.7% 9.2% 68.4% 63.9% 54.5% 0.1% 
Trichlorfon 52.7% 22.6% 8.3% 23.2% 41.9% 33.0% 0.2% 
Dichlorvos 36.1% 1.2% 0.4% 0.7% 17.0% 5.7% 0.3% 
Methidathion 38.1% 18.8% 46.9% 56.5% 31.4% 45.9% 35.9% 
Propetamphos 18.0% 9.5% 36.1% 34.2% 14.5% 32.3% 22.0% 
Ethoprop 40.7% 15.1% 28.5% 37.6% 32.2% 39.0% 9.6% 
Azinphos Me 31.3% 13.4% 31.5% 52.7% 25.2% 36.1% 20.9% 
Pirimphos Me 16.9% 5.7% 41.0% 33.4% 14.1% 31.8% 32.2% 
Tetrachlorvinphos 22.0% 9.0% 25.9% 45.6% 18.2% 30.8% 15.6% 
Fonofos 18.6% 6.2% 38.2% 31.6% 15.6% 25.1% 17.9% 
bensulide 14.2% 6.9% 5.4% 38.3% 12.7% 30.4% 0.1% 
Coumaphos 15.6% 4.2% 33.4% 35.1% 14.7% 29.0% 24.8% 
Chlorpyrifos 13.4% 3.3% 33.7% 17.4% 12.5% 21.5% 23.4% 
Ethion 12.8% 3.8% 30.6% 11.5% 11.7% 18.9% 27.5% 
Tribufos 16.7% 8.0% 29.2% 20.9% 14.6% 25.9% 26.6% 
Temephos 10.3% 2.2% 17.5% 6.2% 9.2% 12.3% 17.1% 



















































































































Figure 104     ChemElut LLE experiment with combination of solvents 
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Accelerated Solvent Extraction (ASE) 
Accelerated solvent extraction is a variant of solid backed LLE. The most common 
carrier is Hydromatrix, a purified form diatomaceous earth marketed by Varian Inc. Just 
like in the case of LLE cartridges, the particles of the solid backing provide a large 
surface area and increase the contact area between the matrix and the eluting solvent. 
ASE extraction is carried out in pressurizable stainless steel cartridges. The application of 
pressure further increases relative surface by pressing the matrix inside the solid particles. 
Applying pressure allows for the use of elevated temperatures, where the pressure 
prevents the solvent from boiling. Using hot solvents for extraction can accelerate the 
process because the lowered viscosities and increased diffusion.  
The solvent of choice for OP pesticides was ethyl acetate. This selection was made based 
on the results using ChemElut cartridges (Table 20, Table 21). Once the extraction 
solvent was selected, extraction temperature, static time and pressure was varied and 
optimized. The results are tabulated in Table 22 and charted in Figure 105 and Figure 
106. Increasing temperatures, static(extraction) time and pressure has a positive effect on 
most compounds, but has a dramatic decrease of recovery on trichlorfon, dichlorvos and 
tetrachlorvinphos. Fro that reason the parameters selected were 5 minutes static time, at 




(Pressure = 1500 PSI, 5 min Static time) 
Temp = 20°C 





MMP 79.9% 81.9% 84.9% 77.4% 79.2% 71.9% 
Acephate 49.5% 59.4% 88.4% 84.6% 51.5% 44.3% 
Oxydem. Me 60.4% 81.6% 94.4% 81.7% 72.3% 73.6% 
Dimethoate 98.5% 92.9% 95.5% 83.8% 93.5% 87.6% 
Trichlorfon 81.2% 64.9% 31.7% 13.9% 59.9% 27.8% 
Dichlorvos 91.2% 34.5% 1.4% 0.1% 34.7% 0.3% 
Methidathion 84.5% 84.3% 89.1% 76.1% 88.8% 79.8% 
Propetamphos 88.7% 91.4% 99.2% 94.3% 85.4% 89.4% 
Ethoprop 81.4% 83.6% 94.9% 93.3% 87.1% 86.7% 
Azinphos Me 87.5% 88.3% 90.6% 72.4% 36.2% 18.1% 
Pirimphos Me 67.0% 71.6% 66.9% 45.1% 71.5% 59.7% 
Tetrachlorvinphos 69.0% 54.7% 27.4% 3.2% 47.0% 18.0% 
Fonofos 81.3% 89.8% 102.1% 97.8% 79.4% 82.4% 
Bensulide 66.6% 81.4% 102.2% 91.6% 81.1% 83.2% 
Coumaphos 74.0% 82.1% 102.2% 99.0% 69.3% 66.1% 
Chlorpyrifos 62.9% 76.8% 93.1% 84.7% 70.3% 70.3% 
Ethion 62.4% 76.8% 100.9% 97.8% 67.5% 70.3% 
Tribufos 64.4% 75.8% 93.0% 90.7% 79.3% 83.3% 
Temephos 56.2% 73.8% 103.2% 98.7% 58.8% 59.9% 










































































Analytes in the order of elution
 
Figure 106   ASE dwell time and pressure effect on recoveries 
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Second step cleanup: normal phase chromatography on SPE cartridges. 
After ASE extraction with ethyl acetate, the samples are clean enough to – after   the lipid 
rich portion of the serum. If these samples are injected without further cleanup, the lipids 
will first concentrate in the column, causing retention time shifts and peak shape changes. 
Next the lipids migrating into the MS, contaminate the ion source and will cause rapid 
signal degradation. For this reason a second step of the cleanup process was developed. 
The approach to further purify the ASE extract was to transfer it to a sorbent filled 
cartridge and wash it with a polar solvent. The elution process was to be fractionated and 
tested for the analytes as well for contaminants.  
The process was carried out as follows:  
The instrument used was Rapid Trace (originally from Zymark corporation, now Caliper 
Life Sciences Hopkinton, MA) 3mL SPE cartridges were filled with 200mg sorbents 
each. The ASE extract (0.35 mL) was then transferred to the Rapid Trace. The automated 
system placed the extract on top of pre-wetted sorbent. Then the cartridge was washed 
with 8mL of ACN. 1 mL fractions were collected and analyzed for all the LC-group 



























Figure 107   Structure of various sorbents 
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The following sorbents were tested:  
- Precipitated silica (Varian, Inc. Palo Alto, CA ) (Figure 107) 
- Alumina (Varian, Inc. Palo Alto, CA) 
- LRA or Lipid removal agent, a synthetic calcium silicate from (Advanced 
Minerals, Santa Barbara, CA) [36] 
- PSA or primary, secondary amine. It is a surface treated silica from Supelco, 
primarily used for foodstuff analysis (Figure 107) 
- Varian HLB (Figure 107) 
The cumulative solids were plotted on Figure 108.   
Next, the cumulative amount of analytes were plotted for each sorbent and the 
cumulative solids/contaminants curve superimposed on each. Figure 109 
All the conventional sorbents (silica, alumina) showed varying affinity to the different 
OP pesticides. LRA did not show a different retention for OP pesticides and 
contaminants. 
The choice came down between PSA and Varian HLB. PSA worked excellent, except 
for its strong retention of acephate. Because acephate is one of our important compounds, 
the choice became the Varian HLB bulk sorbent.  
In the extraction method, the first 1.5mL is saved, concentrated and used for HPLC 
and GC both. As it seen on Figure 109, this cut allows close to 100% of the analytes and 
less than 10% of the contaminants.  
There is a possibility of carryover of trace water. Ethyl acetate can contain up to 7% 
water at room temperature. And the repeated solvent exchanges may not remove all of it. 
Trace of water can damage GC columns over time. To remove residual water, a 
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combination of 200 mg bulk HLB and the same amount of anhydrous sodium sulfate was 
tried. Dichlorvos. Tetrachlorvinphos and phosmet showed decreased recoveries (Table 
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Figure 109, continued: Elution of OP pesticides over different sorbents 
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 Average Recoveries Standard Deviations 
 200 mg HLB 
200 mg 
HLB 




200 mg HLB 
+ 200 mg 
Na2SO4 
Mevinphos 69.2% 36.8% 7.0% 17.2% 
Chlorethoxyfos 55.8% 67.9% 4.4% 9.0% 
Phorate 59.7% 75.9% 3.3% 7.7% 
Cadusafos 82.7% 81.9% 6.3% 12.7% 
Dicrotophos 82.2% 73.7% 12.0% 12.1% 
Sulfotepp 62.4% 50.1% 2.4% 10.7% 
Diazinon 71.6% 91.5% 16.8% 58.3% 
Terbufos 57.1% 69.5% 13.2% 38.0% 
Fonofos 72.2% 94.1% 16.7% 62.1% 
Phostebupirim 62.5% 73.3% 9.3% 20.1% 
Chlorpirifos Me 50.3% 46.9% 6.0% 1.7% 
Me parathion 45.9% 64.6% 14.1% 3.4% 
Malathion 64.9% 37.4% 12.1% 9.5% 
Fenthion 55.2% 58.1% 9.7% 4.4% 
Et Parathion 47.0% 70.6% 21.3% 26.2% 
Fenamiphos 56.7% 69.5% 13.7% 3.0% 
Profenofos 31.7% 12.6% 11.5% 5.9% 
Phosmet 30.1% 2.2% 21.1% 0.8% 
Phosalone 62.6% 74.7% 13.0% 9.4% 
Table 23 Two step cleanup: recoveries of GC group OP pesticides.  
Concentrations are 500ng/mL 
 
 Average Recoveries Standard Deviations 
 
200 mg HLB 
200 mg 
HLB 
 + 200 mg 
Na2SO4 
200 mg HLB 
200 mg HLB 
+ 200 mg 
Na2SO4 
MMP  65.9% 66.0% 1.0% 2.3% 
Acephate  43.9% 50.7% 2.5% 14.7% 
Oxydem Me  65.5% 63.7% 8.7% 9.0% 
Dimethoate  80.2% 80.9% 9.8% 5.6% 
Trichlorfon  53.6% 27.5% 11.2% 12.3% 
Dichlorvos  47.2% 18.3% 40.1% 1.5% 
Methidathion  77.9% 74.6% 8.0% 5.7% 
Ethoprop  75.6% 82.3% 2.7% 11.2% 
Propetamphos  69.9% 77.4% 1.7% 14.2% 
Azinphos_Me  69.3% 66.2% 8.5% 5.9% 
PirimphosMe  60.6% 51.4% 9.2% 5.1% 
Tetrachlorvinphos  48.4% 14.2% 14.7% 11.2% 
Fonofos  68.1% 74.8% 0.4% 7.2% 
Bensulide  63.9% 73.3% 4.1% 8.3% 
Coumaphos  64.8% 72.6% 6.2% 15.1% 
Chlorpyrifos  62.2% 69.1% 4.7% 10.8% 
Ethion  58.9% 73.0% 2.5% 13.5% 
Tribufos  63.9% 76.9% 0.6% 11.5% 
Temephos  52.1% 65.3% 3.9% 16.1% 
Table 24 Two step cleanup: recoveries of LC group OP pesticides 






































Analytes in the Order of Elution
 
























Analytes in the Order of Detection
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Figure 112   Sample dispersion process prior ASE extraction 
Frozen unknown and blank serum samples were first thawed out. 1 mL of each was 
aliquoted into 15 mL conical bottom centrifuge tubes. All samples were spiked with 
10µL internal standard solution. Each centrifuge tubes were mixed with vortex mixer for 
ten seconds. Next, the standard series were spiked with 10µL standard solutions. The 
centrifuge tubes were vortex mixed once more for ten seconds. 
In equal number as the centrifuge tubes, ASE cartridges were prepared as follows: 
Cartridge body and cap were hand tightened, and then one fiberglass based filter disc 
was placed inside. 10 mL of Hydromatrix absorbent was placed in the cartridges.  
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The same number of 20 mL flat bottomed vials was also filled with 10 mL Hydromatrix. 
Each serum sample was then pipetted on top of the corresponding glass vial, where the 
Hydromatrix promptly absorbed it. Each vial then was vortex mixed at high speed to 
disperse the serum in the Hydromatrix. The absorbent/serum mix was then transferred in 
a previously “half filled” cartridge.  
A second filter disk was placed on top of the cartridge; the top cap was put in place 
and hand tightened. The cartridges were placed on the ASE rack, the receptacle vials 
were put in place and labeled. The extraction solvent reservoir was filled with fresh ethyl 
acetate and 1500 PSI nitrogen pressure applied.  
The extraction process consisted of two extraction cycles of ten minutes duration at 
1500 PSI and room temperature. Machine purge (automatic flush between samples) was 















Figure 113  Accelerated solvent extractor 
 
After the extraction the receptacle vials were collected, and the ethyl acetate extract 
was transferred into 50 ML Turbovap II tubes (with 0.5 mL tips). The sensors of the 
Turbovap II evaporator were customized to signal endpoint at 350µL instead the regular 
0.5 mL. Applied nitrogen pressure was 13 PSI, the water bath temperature was adjusted 
to 35°C. 
The concentration took place in thee steps:  
First the ethyl acetate was blown off until the sensor stopped the process, or 
approximately .35 mL. Next 5 mL acetonitrile was added to each tube and the process 
repeated. Finally an other 5 mL of acetonitrile was added to each tube, but this time the 
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evaporator was programmed, to stop the drying process at 6 minutes after sensors detect 
the meniscus. This program resulted in approximately 100 µL final extract volume in 
acetonitrile.  





Dry to 0.5 mL
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Figure 114  Comprehensive cleanup diagram 
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Determination of Instrument Detection Limits LC-MS-MS and GC-MS-MS groups 
 
LODs were determined by using a series of neat standard solutions. The starting 
concentrations were 1.00, 2.50, 5.00, 10.00, 25.00, 50.00, 100, 250 and 500 ng/mL, 
identical concentrations for each analyte. These standards were previously prepared in 
acetonitrile. 
The internal standard stock solution was of the concentration of 2.5 µg/mL in acetonitrile. 
This solution was diluted twenty times with acetonitrile. The resulting diluted internal 
standard solution had the concentration of 125 ng/mL for each isotope labeled standard. 
To make the standard series for the “LC analyte group”, 10 µL of the native standard 
solution was pipetted into a LC vial, 10 µL of diluted internal standard solution added, 
and then followed with 20 µL of acetonitrile. This process was repeated for each 
concentration levels. The resulting series had concentrations of 0.250, 0.625, 1.25, 2.50, 
6.25, 12.5, 25.0, 62.5, 125 ng/mL in serum €for native compounds and 31.3 ng/mL for 
isotope labeled standards. The standard series samples were injected at 1µL each, using 
the HPLC-MS-MS method described previously. 
For the “GC analyte group” the same standard series was used as a starting point, but 
with a different preparation: 20µL of the original standard series, then 20 µL diluted 
internal standard was pipetted into a 15 mL conical bottom centrifuge tube. The tube then 
was placed in a Turbovap LV evaporator.  Temperature was 40°C, nitrogen pressure was 
set to 15 PSI. The drying process was carefully monitored and stopped just before 
complete dryness. 80 µL toluene was added to the centrifuge tube, mixed thoroughly on a 
vortex mixer, then transferred in a GC vial and capped. 
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The 1 µL of the prepared samples were injected in the GC-MS-MS system.  
For the LC and GC experiment both, three injections were made.  
 
The LC-MS-MS experiment was only conducted in positive APCI mode because – as 
it was shown earlier  – not all OP pesticides ionize in ESI mode. 
Since not all OP pesticides ionize in negative mode, positive ionization was selected.  
LOD-s were determined as follows: 
For each compound a linear calibration plot was established by using linear regression 
and 1/concentration weigthing. The vertical axis of the calibration curve was the area 
ratio (area of analyte peak divided by the internal standard peak area). The horizontal axis 
was the concentration. Once the calibration curve was defined, for each concentration and 
each analyte a “calculated concentration” was determined, based on the slope and 
intercept of the calibration curve and the response factor for the particular measurement.   
Next, for each concentration of the standard series the standard deviation of the 
“calculated concentrations” was determined and plotted over the actual concentrations. 
Limit of detection was determined by establishing a “standard deviation – concentration” 
relationship trend line and extrapolating it to zero concentration. LOD is defined as three 
times the expected value of the standard deviations of the calculated concentrations at 
zero concentration.   
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Effect of drying the samples. 
During the cleanup process the samples are dried in the presence of acetonitrile to 
remove water and ethyl acetate. To determine the effect of the drying process, and to 
determine if complete dryness causes sample loss, the following experiment was carried 
out: 
A stock solution was prepared which contained all the OP analytes at 500 ng/mL: 
concentration, but no internal standard. 0.5 mL of this solution was added to Turbovap II 
tubes started to dry the samples at 40°C and 12 PSI nitrogen pressure. Drying was 
stopped at 10 and 20 minutes, the samples reconstituted to 0.5 mL and internal standard 
added. The experiment was done in multiples of 3. 
A second set of experiments was also completed with one difference: at the beginning 
approximately 5 µL dodecane was added, the experiment was similarly stopped at 10 and 
20 minutes. Everything was carried identically to the first set of experiment. 
The reconstituted samples were analyzed with the HPLC-MS-MS system; response 
factors were averaged for identical samples then compared 
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MMP 100.00% 45.20% 21.11%   100.00% 61.92% 41.76% 
Acephate 100.00% 86.57% 66.91%   100.00% 94.46% 79.76% 
Oxydemethon 
Methyl 100.00% 92.93% 101.83%   100.00% 92.46% 98.10% 
Dimethoate 100.00% 85.47% 76.35%   100.00% 87.99% 84.31% 
Trichlorfon 100.00% 28.00% 15.10%   100.00% 52.35% 22.05% 
Dichlorvos 100.00% 6.67% 3.37%   100.00% 22.47% 3.09% 
Methidathion 100.00% 94.91% 91.72%   100.00% 99.42% 98.68% 
Propetamphos 100.00% 86.07% 51.42%   100.00% 97.18% 76.52% 
Ethoprop 100.00% 35.29% 11.90%   100.00% 76.42% 19.36% 
Azinphos Me 100.00% 99.95% 108.24%   100.00% 97.25% 102.03% 
Pirimphos Me 100.00% 77.67% 54.49%   100.00% 84.65% 70.65% 
Tetrachlorvinphos 100.00% 120.74% 125.45%   100.00% 121.15% 146.78% 
Fonofos 100.00% 38.89% 5.64%   100.00% 76.56% 20.09% 
Bensulide 100.00% 104.90% 111.46%   100.00% 100.20% 107.56% 
Coumaphos 100.00% 103.83% 108.55%   100.00% 101.26% 105.96% 
Chlorpyrifos 100.00% 74.77% 44.84%   100.00% 87.31% 66.36% 
Ethion 100.00% 99.13% 95.45%   100.00% 98.24% 103.38% 
Tribufos 100.00% 99.19% 84.62%   100.00% 97.97% 92.87% 
Temephos 100.00% 110.98% 118.84%   100.00% 111.10% 111.43% 
Table 25   Effect of  drying on recoveries of LC compound group, with and without addition of 
dodecane "catching solvent" 
From Table 25 and figures  





































Analyte Loss During Turbovap Drying






































Construction of calibration curves 
First a series of stock solutions was prepared for each analyte. The stock solutions 
were 1000 µg/mL concentration in acetonitrile. By blending the forty stock solutions at 
equal volume, a 25 µg/mL blended stock was made. Using the blended stock as a starting 
solution, the following standard concentrations were developed by gradual dilution: 
1.00, 2.50, 5.00, 10.0, 25.0, 50.0, 100, 250, 500, 1000 ng/mL 
10µL of above standards was added to 1 mL serum resulting in the following 
concentration series: 
0.010, 0.025, 0.050, 0.100, 0.250, 0.500, 1.00 ng/mL analyte in serum 
Calibration curves were constructed following the isotope dilution method. For the 
forty compounds of interest we obtained seventeen isotopically labeled variants for using 
them as internal standards. A mixture of internal standards was dissolved in acetonitrile at 
a concentration of approximately 0.25 ng/mL. This level was selected because all the 
reference compounds are well detectable at this concentration. Increasing the amount of 
reference compounds may causes problems because they contain small amounts of the 
non labeled variant. This can introduce an “offset amount of” analyte, not coming from 
the matrix. 
For each analyte a corresponding internal standard was selected. After the analysis 
was completed the date files were collected and evaluated using Thermo Finnigan’s 
Xcalibur software. For all calibration curves the linear model was chosen with 1/x 
weighing. 1/x weighing puts more emphasis to the lower concentration points. This is 
more desirable for trace analysis. 
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MMP_Q
Y = 0.0183435+0.578204*X   R^2 = 0.9995   W: 1/X





















Name Type of Label Location of the Label 
Acephate D6 Deuterated dimethyl 
Bensulide D14 Deuterated diisopropyl 
Chlorpyrifos D10 Deuterated diethyl 
Chlorpyrifos methyl D6 Deuterated dimethyl 
Coumaphos D10 Deuterated diethyl 
Dimethoate D6 Deuterated dimethyl 
Disulfoton D10 Deuterated diethyl 
Ethyl parathion D10 Deuterated diethyl 
Fenthion D6 Deuterated dimethyl 
Fonofos** 13C6 
Malathion D10 Deuterated diethyl 
Methamidophos D6 Deuterated dimethyl 
Oxydemeton methyl D6 Deuterated dimethyl 
Phorate 13C4 
Phosmet D6 Deuterated dimethyl 
Sulfotepp D20 Deuterated tetraethyl 
Terbufos 13C4 
Table 26   Available isotope labeled internal standards  
Figure 117   Methamidophos Calibration Plot 
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LOD-s for the LC group 
Instrument LOD-s were determined by injecting a series of neat standards dissolved in 
acetonitrile, thus not performing the actual cleanup. Final LOD-s were calculated from 
triplicates as described above: 
 




















Table 27   LC group compound detection limits in pure form 
 
Precision and accuracy of the method  
 
Precision of the method is described by the standard deviation of measurements at a 
certain concentration. Accuracy is the quality that compares the measured values with the 
expected concentrations. Both, accuracy and precision are displayed as percentages: the 
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mean of measured concentration/expected concentration ratio and the relative standard 
deviation, respectively. 
 We used two concentrations, 0.25 ng/mL and 5 ng/mL to show accuracy and 
precision of the method  
  Standard Deviation   Accuracy 
OP concentration 0.25 5  0.25 5 
in serum [ng/mL] [ng/mL]  [ng/mL] [ng/mL] 
Analyte           
MMP 5.5% 1.8%  97% 100% 
Acephate 16% 5.2%  94% 98% 
Oxydemethon Me 0.2% 10%  124% 95% 
Dimethoate 10% 6.4%  93% 99% 
Trichlorfon 8.3% 8.3%  81% 99% 
Dichlorvos 14% 8.1%  154% 97% 
Propetamphos 8.7% 6.4%  102% 97% 
Methidathion 20% 4.9%  93% 94% 
Ethoprop 9.8% 5.3%  103% 97% 
Azinphos Methyl 20% 4.4%  98% 97% 
Pirimphos Methyl 4.7% 3.2%  102% 96% 
Tetrachlorvinphos 14% 3.5%  93% 96% 
Fonofos 9.4% 4.9%  100% 99% 
Bensulide 12% 4.6%  83% 95% 
Coumaphos 6.2% 4.6%  99% 98% 
Chlorpyrifos 6.8% 4.6%  95% 99% 
Ethion 11% 3.7%  102% 97% 
Tribufos 17% 4.4%  96% 97% 
Temephos 21% 7.1%  89% 102% 





Deviation   Accuracy 
OP concentration 0.25 5  0.25 5 
in serum [ng/mL] [ng/mL]  [ng/mL] [ng/mL]
Analyte           
Mevinphos 9.1% 7.9%  94% 107%
Chlorethoxyfos 3.1% 5.3%  88% 100%
Dicrotophos 19% 1.4%  93% 119%
Sulfotepp 5.9% 5.3%  76% 105%
Cadusafos 6.7% 5.1%  90% 109%
Phorate 5.1% 17%  99% 100%
Diazinon 0.7% 1.6%  78% 110%
Fonofos 19% 3.4%  97% 102%
Phostebupirim 19% 6.8%  103% 99%
Chlorpyrofos Me 13% 2.8%  91% 99%
Me Parathion 20% 8.7%  110% 101%
Malathion 5.0% 13%  138% 101%
Fenthion 18% 7.8%  85% 106%
Et Parathion 21% 6.2%  95% 102%
Fenamiphos 10% 19%  81% 118%




Deviation   Accuracy 
OP concentration 0.25 5  0.25 5 
in serum [ng/mL] [ng/mL]  [ng/mL] [ng/mL]
Analyte           
Mevinphos 18% 2.4%  118% 97%
Chlorethoxyfos 10% 11%  75% 104%
Dicrotophos 19% 8.6%  107% 101%
Sulfotepp 5.1% 2.2%  105% 103%
Cadusafos 15% 3.0%  102% 101%
Phorate 2.8% 1.2%  95% 99%
Diazinon 23% 4.0%  96% 112%
Fonofos 5.1% 4.1%  93% 98%
Phostebupirim 5.6% 2.2%  106% 97%
Chlorpyrofos Me 44% 8.0%  109% 103%
Me Parathion 43% 7.2%  167% 100%
Malathion 45% 17.6%  99% 107%
Fenthion 46% 3.8%  126% 100%
Et Parathion 2.3% 22%  98% 116%
 
To to test the precision of the method, serum samples of three concentrations were 
prepared: .250 ng/mL, 1 ng/mL and 5 ng/mL. These samples were prepared, spiked and 
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extracted individually, then the concentrations were determined and plotted. At this point 
was it determined that was it determined that length of extraction time plays an important 
role when extracting larger number of samples on ASE. The ASE is a carousel system, 
where the assembled cells with serum inside are waiting for their turn to be extracted. 
While the cells wait at room temperature, enzymatic and hydrolytic decomposition is 
taking place. This theory was tested by keeping spiked serum at room temperature for up 
to 24 hrs and testing recoveries at different times. As it shows in  
Figure 118, about half of the compounds lose more than 50% of their original 
concentration. If, - as in the original method – we use two five minutes static cycles when 
all the other time adds up a 24 cartridge carousel takes over six hours to process. This 
time delay while working with full carousels, can and do effect detection limits and the 
precision of the measurement. The main problem is, that not all compounds have their 
own isotope labeled equivalent as internal standard. Different compounds hydrolyze at a 
different rate and this will effect response factors and calculated concentrations.  
The first attempt to solve the decomposition problem was to add 100µL 50 mM EDTA 
solution. The idea was that EDTA will chelate the metal ions in the A-esterases and 
denature these enzymes. Comparing Figure 118 and Figure 119 it is clear that the EDTA 
did not have the desired effect.  
The second approach was to fine-tune the first part of the sample preparation. First, 
the ASE pressurized dwell time was reduced from 2x5 to 2x2 minutes, but using the same 
amount of ethyl acetate. This alone reduced the total run time to 3 hrs.  
Second, the sample dispersion method was altered. Instead of adding the serum directly 
to the filled cartridge, it was separately pre-dispersed in 10mL of Hydromatrix. Lastly, 5 
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mL of ethyl acetate was added to the cartridge before closing, to denature any enzyme 
and to begin the extraction process while waiting in the line. The results were tabulated in 
Table 29. At the end of the table, averages were calculated for the range of OP pesticides 
covered (HPLC group).  
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Figure 119   Decomposition of OP pesticides in serum, 100µL 50 mmolar  EDTA 







no vortex, no ethyl acetate   5 mL ethyl acetate but  no vortex mixing 
  5 mL ethyl acetate,  
vortex mixing     
Concentration [ng/mL] 
Analyte 0.25 1 5   0.25 1 5   0.25 1 5 
MMP 6.9% 3.2% 3.8%  4.5% 6.1% 2.5%  7.4% 8.6% 1.6%
Acephate 30.4% 9.9% 3.8%  25.2% 14.7% 4.2%  10.2% 11.0% 2.9%
Oxydem Me 20.8% 44.3% 26.1%  26.9% 30.3% 11.7%  N/F 16.8% 11.3%
Dimethoate 11.2% 9.2% 8.1%  13.3% 6.1% 8.7%  11.0% 11.8% 4.0%
Trichlorfon 100.0% 108.3% 75.5%  19.8% 12.7% 12.2%  9.0% 11.9% 4.7%
Dichlorvos N/F N/F N/F  N/F 19.2% 38.9%  15.0% 26.3% 24.3%
Methidathion 25.0% 10.3% 5.9%  28.3% 7.4% 12.2%  12.0% 10.1% 7.3%
Ethoprop 18.9% 9.4% 5.7%  24.3% 11.5% 13.8%  18.5% 7.2% 7.1%
Propetamphos 38.3% 37.9% 12.0%  60.2% 31.2% 26.6%  13.0% 11.1% 10.1%
Azinphos Me 69.3% 20.7% 9.2%  21.1% 18.9% 9.8%  26.4% 5.5% 10.7%
Pirimphos Me 37.2% 32.8% 21.3%  16.8% 10.4% 32.5%  5.7% 9.9% 6.5%
Tetrachlorvinphos 160.4% 123.0% 95.6%  49.0% 18.4% 19.7%  22.2% 10.5% 8.4%
Fonofos 23.6% 8.1% 4.2%  7.0% 9.5% 6.4%  18.2% 6.2% 5.3%
Bensulide 56.2% 15.8% 18.8%  47.9% 28.8% 18.1%  15.6% 13.0% 9.2%
Coumaphos 19.2% 14.5% 10.9%  15.7% 5.1% 12.7%  8.5% 9.6% 6.4%
Chlorpyrifos 23.2% 20.8% 12.1%  31.1% 3.5% 8.7%  22.2% 15.1% 10.7%
Ethion 15.3% 7.6% 7.1%  8.8% 6.3% 20.3%  5.5% 9.8% 5.1%
Tribufos 34.7% 12.5% 13.7%  23.2% 25.8% 41.9%  15.4% 14.2% 4.2%
Temephos 39.5% 39.3% 27.5%   53.7% 36.9% 24.5%   26.6% 13.2% 4.1%
Average 40.6% 29.3% 20.1%  26.5% 15.9% 17.1%  14.6% 11.7% 7.6%
Table 29   Relative standard deviations of three concentration of analytes -  HPLC group 
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Detection limits for the cleaned up serum samples are sown in Table 30 




















Table 30  Limits of detection of the LC group compounds, serum samples 
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The problem with azinphos methyl and the power of tandem mass spectroscopy 
Analyzing real samples from the field, several clear “hits” were detected for azinphos 
methyl. The peaks were clear, well defined, but the concentrations determined by using 
the “quantitation ion” (318->132) were substantially different from those indicated by the 
conformation ion. (318->77). QC results were within the expected range for both 
transitions.  
Further investigation has shown that phosmet co-elutes (not fully resolved) with 
azinphos methyl and has the same molecular mass, 317. This usually isn’t a problem 
using tandem MS, but in this case one of the fragments, 77 is the same. Phosmet is 
analyzed in the GC-MS-MS part of the method, so this coincidence only became apparent 
while comparing ion ratios of the transitions 318->132 and 318-77 in standards, QC-s 
and actual samples. 

































Figure 120  Azinphos methyl chromatography, monitoring all four major transitions for azinphos methyl 
and phoseth 
 
Figure 121  Phosmet chromatography, monitoring all four major transitions for azinphos methyl and 
phosmet 
RT: 0.00 - 30.01


























































TIC F: + c APCI sid=10.00  SRM ms2 
318.000@cid51.00 [76.500-77.500]  MS  
ICIS 0801010AzMe05_081015185749
NL: 1.27E4
TIC F: + c APCI sid=10.00  SRM ms2 
318.001@cid21.00 [131.500-132.500]  
MS  ICIS 
0801010AzMe05_081015185749
NL: 5.22E3
TIC F: + c APCI sid=10.00  SRM ms2 
318.002@cid26.00 [103.500-104.500]  
MS  ICIS 
0801010AzMe05_081015185749
NL: 1.11E4
TIC F: + c APCI sid=10.00  SRM ms2 
318.003@cid24.00 [124.500-125.500]  
MS  ICIS 
0801010AzMe05_081015185749
NL: 1.72E3
TIC F: + c APCI sid=10.00  SRM ms2 
318.004@cid33.00 [159.500-160.500]  
MS  ICIS 
0801010AzMe05_081015185749
NL: 6.63E2
TIC F: + c APCI sid=10.00  SRM ms2 
318.005@cid49.00 [132.500-133.500]  
MS  ICIS 
0801010AzMe05_081015185749
NL: 5.94E3
TIC F: + c APCI sid=10.00  SRM ms2 
318.006@cid52.00 [76.500-77.500]  MS  
ICIS 0801010AzMe05_081015185749
NL: 2.04E3
TIC F: + c APCI sid=10.00  SRM ms2 
318.007@cid56.00 [104.500-105.500]  
MS  ICIS 
0801010AzMe05_081015185749
318 ->   77 
 
 
318 -> 132 
 
318 -> 160 
 
 
318 -> 133 
 
RT: 0.00 - 30.00
















































TIC F: + c APCI sid=10.00  SRM ms2 
318.000@cid51.00 [76.500-77.500]  MS  
ICIS 0801010azme06_081015183815
NL: 1.31E3
TIC F: + c APCI sid=10.00  SRM ms2 
318.001@cid21.00 [131.500-132.500]  
MS  ICIS 0801010azme06_081015183815
NL: 6.58E2
TIC F: + c APCI sid=10.00  SRM ms2 
318.002@cid26.00 [103.500-104.500]  
MS 0801010azme06_081015183815
NL: 1.17E3
TIC F: + c APCI sid=10.00  SRM ms2 
318.003@cid24.00 [124.500-125.500]  
MS  ICIS 0801010azme06_081015183815
NL: 9.59E4
TIC F: + c APCI sid=10.00  SRM ms2 
318.004@cid33.00 [159.500-160.500]  
MS  ICIS 0801010azme06_081015183815
NL: 1.63E4
TIC F: + c APCI sid=10.00  SRM ms2 
318.005@cid49.00 [132.500-133.500]  
MS  ICIS 0801010azme06_081015183815
NL: 2.85E4
TIC F: + c APCI sid=10.00  SRM ms2 
318.006@cid52.00 [76.500-77.500]  MS  
ICIS 0801010azme06_081015183815
NL: 1.10E4
TIC F: + c APCI sid=10.00  SRM ms2 
318.007@cid56.00 [104.500-105.500]  
MS  ICIS 0801010azme06_081015183815
318 ->   77 
 
 
318 -> 132 
 
318 -> 160 
 
 



















Figure 122   Transition 318 -> 77 signal from azinphos methyl and phosmet 
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Chapter 4 Discussion 
The firs step of the method is the cleanup and it was to be developed last. Detection 
methods have to be established first, so the effectiveness of different approaches to the 
cleanup may be evaluated. 
The purpose of the cleanup procedure is twofold: First to remove those contaminants 
from the sample that interfere with the detection or analytical separation. In serum these 
contaminants are mainly salts, proteins and lipids.[37] . 
It is also important to concentrate the sample. The available serum sample is usually 1-
5 mL. LC and GC methods only inject a few micro liters of sample. The solution 
containing the analytes, have to be concentrated.  
The most important cleanup consideration in our work is that it has to be universal. 
The serum samples are usually part of studies, supplies are limited and most often they 
came from an anonymous individual. The cleanup and analytical methods are destructive. 
Once a sample is processed that amount of serum is used up, it can not be replenished.  
Considering availability of instrumentation and materials, the usual approach to 
cleanup is as follows: 
- Solid phase extraction (SPE) 
- Lyophilization followed by solid-liquid extraction 
- Various forms of liquid-liquid extraction (LLE) 
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Solid phase extraction 
Solid phase extraction is the usual first and preferred approach. It is specific, uses less 
solvent than the varieties of LLE methods. It is also highly automatable. Methods 
developed for individual tubes are easily transferred to 96 well plates and automated 
liquid handlers. The problem with SPE in this application is the range of compounds and 
consequently the range of their properties. For example: some are extremely water 
soluble (methamidophos (MMP), acephate) others are very lipophilic. Some are ionizable 
in solution, most are not. This problem was confronted in a previous work [35], where 
SPE had to be abandoned. (The matrix was urine.) The reason was that the highly 
hydrophilic compounds could not be retained sufficiently on any sorbent and washed. 
Acephate and MMP always eluted with wash step. Eventually freeze drying and liquid –
solid extraction with dichloromethane had to be applied.  
Lyophilization 
Lyophilization or freeze drying was tried as described in the experimental section, but 
if did not bring the same results as in urine matrix. The most likely explanation is that 
when serum dries, it forms a hard crust leaving limited area for the solvent to interact 
with. Urine on the other hand, - when freeze dried – turns into a crumbling powdery 
material which has a very large surface are.  
Liquid- Liquid extraction  
The method was developed with the intention to run many samples in the future, so 
LLE in a separatory funnel was never considered. LLE was first tested using ChemElut 
LLE cartridges. Using these cartridges shoved promise, but we did not have the 
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equipment to automate.  For this reason and because of the need for better control the 
LLE portion of the method was transferred to ASE, where timing, temperature and 
pressure is controlled. As described previously, ethyl acetate solvent and 1500 PSI 
(~10,000 kPa) at room temperature was chosen as operating parameters. While the many 
of the more lipophilic (late eluting in HPLC) compounds improve their recovery at higher 
pressures and temperatures, three analytes: trichlorfon, dichlorvos and tetrachlorvinphos 
show abnormally low recoveries at alleviated pressure temperature or dwell time. The 
commonality of these three compounds is that they have chlorine near the ester bond, 
possibly weakening it and predisposing it to thermal breakdown. Interestingly, these three 
compounds are also among those five compounds in the GC-MS-MS section that were 
shown unpredictable retention behavior. 
Different structural properties of OP pesticides were examined and correlated with 
ASE extraction data. Only the LC group was used because – as it was pointed out earlier 
in this chapter- after ASE extraction the samples are not clean enough for GC-MS-MS. It 
was found that the strongest correlation is between the number of nitrogen atoms in the 
molecule and the recovery percentage. Interestingly, the Correlation factor between 
log(Kow) and recovery is only 0.23, while the same between the number of nitrogen 





Figure 123   Dependence of ASE recovery on the number of  nitrogen atoms in the OP molecule. Emphasis 
on the halogenated species. 






















































   
Novelty and significance of the method 
 
Currently there are three different approaches to analyze OP exposure. These methods 
can be grouped as indirect and direct (parent compound) methods. 
 
- Urine Analysis of OP metabolites [13] 
Most large studies use urinary analysis of OP metabolites. This method gives a 
window to OP exposure of few days. It is also a cumulative indicator of OP exposure. 
Advantage of the urinary assay is that urine samples are easy and non-invasive to 
obtain and clean up is relatively easier than that of blood products. Some OP pesticides 
like chlorpyrifos, coumaphos, diazinon, parathion, malathion have specific metabolites 
detectable in urinary assay. 
While urinary metabolite assay is the most common analysis of OP exposure, it has 
two shortcomings. Many OP pesticides do not have easily detectable specific metabolites, 
so the source of non specific metabolites has to be estimated from external data, such as 
usage statistics. The second and more general shortcoming is, that – as shown later on the 
chlorpyrifos example – the source of metabolites may be environmental degradation prior 
exposure. The degradation products are not cholinesterase inhibitors, not known to be 
toxic. This results in the underestimation of the health outcome – exposure correlation. 
- Butyryl Cholinesterase adduct assay  [38, 39] 
Butyryl cholinesterase is a scavenger of anti-cholinesterase compounds and it is 
abundantly available in serum. The OP compounds of interest form adducts at the active 
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sites, lose their specific group. These adducts may be detected for a few months after 
exposure.  
Comprehensive OP assay for OP adducts is currently under implementation at CDC. It 
will provide an alternative to the urinary assay.  
It also will inherit one of the shortcomings of the above method: non-specificity. On 
the other hand, environmental degradation products do not form serum cholinesterase 
adducts. 
2 Parent compound methods 
 
Direct analysis of the parent compounds in serum 
This is the method developed in this dissertation. 
As shown in the graph, after exposure the first opportunity for detection is in the 
blood. While the window of detection is short, hours to few days depending the type of 
OP, sensitivity and metabolic conditions, direct analysis has significant advantages.  
- It is a specific method. The compounds of interests are directly analyzed, 
exposure is determined, not deducted from secondary markers. (metabolites) 
- It is a non-cumulative method, like a snapshot of state of OP exposure of a 
group in question.  
- It relies on a regulated fluid: blood, so subsequent concentration correction is 
not necessary. 
- It eliminates the otherwise always present question of the source of the 




A practical significance of the method described in the thesis is that it is a sensitive 
method, with sub ng/mL limits of detection, useful for exposure studies, that covers all 39 
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Table 32 Summary of OP assays for human exposure 
 
The Chlorpyrifos example. 
 
Chlorpyrifos is a broad-spectrum, chlorinated organophosphate insecticide, acaricide 
and nematicide. It was first introduced in 1965, to control insects on food and animal feed 
crops. It is one of the most commonly used insecticide. It is still used for food crops, golf 
courses turf, non-structural wood treatment for termite control. 
Once ingested, chlorpyrifos metabolizes according the mechanism illustrated in Figure 
124. 
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In water and soil chlorpyrifos also degrades in a similar pattern. ( 
 
 
Figure 125) Both degradation pathway includes the oxon formation step. Environmental 
decomposition does not include the glucoronization step. Non specific metabolites are 
deithylphosphate and diethyl thiophosphate, while specific metabolites are 3,5,6 
trichloropiridinol and 3,5,6 trichloropiridinol glucoronide.  
While specific metabolites may provide a way to specify the OP in question, the 
source of the specific metabolite may be environmental degradation, prior ingestion and 
not metabolism of the original OP. This alternate pathway clouds the speciation. It also 
makes it difficult to assign health effects to OP exposure, since the metabolic pathway 
and the environmental degradation partially overlap. 
The same is true for the non specific metabolites. Urinary assay of non specific 
metabolites is used to track cumulative exposure to OP pesticides. To interpret the 
results, one needs to have knowledge of the composition and types of the pesticides the 
population is exposed to. But even with this information it is not certain if the non 
specific metabolites detected in the urine were results of actual OP exposure or prior 
environmental degradation.[40] 
Clarification of the OP exposure may be approached in several ways. 
One is the above mentioned determination of the composition of likely exposure from 
agricultural usage and environmental data. 
Second approach is – which was developed in this thesis – is to use the presence of 




Why is the method unique? 
 
The method developed is unique for two reasons: 
 
1.  The range of compounds it detects. 
This method covers 35 of the 39 EPA registered OP pesticides. Before, the highest 
number was 21. [23].  
Serum methods covering a limited number of OP pesticides existed before, but they 
concentrated on poisoning cases where the possible toxicants are already known and the 
concentrations are relatively high. These forensic cases don’t need high sensitivity or 
selectivity.  
 
2.   Limits of detection 
Detection limits are 1-2 orders of magnitude lower than previous methods, covering a 
larger number of OP pesticides.   
The reasons for this increased limits of detection is three fold:  
- The ASE / ethyl acetate extraction provides recovery through the range of OP 
pesticides. 
- For the “GC group compounds” The secondary, normal phase cleanup (with 
HLB sorbent) eliminated much of the lipid contaminants, allowing for  
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chemical ionization for serum sample extracts. This purer extract also helped 
lowering the chemical background. 
- Tandem mass spectrometry was used throughout the method. Tandem MS 
adds an other layer of selectivity and increases LOD 
 
This lower detection limit, combined with the wide range of detectable compounds 
makes the method developed in this dissertation a uniquely applicable assay for the 
“snapshot detection” of OP pesticide exposure. 
 
The cleanup and sample concentration part of the method may be used to detect of low 











































































































Figure 125   Environmental degradation of  chlorpyrifos 
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CHAPTER 4   APPENDIX 
Appendix 4A: Suggested fragmentation of OP pesticides 
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Appendix 4B: Determination of recovery using internal standard 
Recoveries are the fractions of the analytes extracted after a clean up step, or after the 
entire cleanup process. To determine recoveries one need two samples of the matrix, A 
and B. Sample A is spiked with a predetermined amount of analyte and homogenized. 
Sample B is not spiked. Next both of the samples are put through the clean up process. 
After completing the cleanup, the same amount of analyte added to B as it was added 
sample A before. Next internal standard is added to both A and B and homogenized. 
Both extracted and concentrated samples A and B is analyzed for all compounds of 
interest and response factor is determined for all in A and B. 




frec =  
Equation 1   Calculation of recoveries fA and fB are the response factors for the particular analyte in 
samples A and B 
Finally recovery calculations are done on multiple sample pairs, average recoveries 
and standard deviations are calculated. The experimental process is illustrated on  
Figure 126. This approach of determining recoveries eliminates the matrix effect, 
















Figure 126   Flow chart of determining recoveries of a given cleanup process 
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Appendix 4C:  Determination of limit of detection (LOD) 
 
Limits of detections were calculated as described by Taylor [41] and illustrated on 
Figure 127. Multiple calibration series were plotted and for each known concentration 
(“actual concentration” on Figure 127 ) the response factor was determined. From the 
response factor, “calculated concentrations” were computed, using the calibration curve. 
As shown in the second part of Figure 127, the standard deviations of the calculated 
concentrations ware plotted against the actual concentrations. By fitting a line to the 
standard deviation series of data points, the intercept was determined. The intercept is the 
standard deviation of the calculated concentration at zero concentration, or S0. Three 
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